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ABSTRACT
N ovel C isp latin  D erivatives -  S y n th esis , C haracterization  
and C jrtotoxicity in  Breast Cells
by
K yle r E lizabe th  E lw e ll
D r. S tephen W. C arper, E xam in a tion  C om m ittee C h a ir 
P rofessor o f C hem istry 
U n ive rs ity  o f Nevada, Las Vegas
C is -d ia m m ine d ich lo rop la tin u m  (II) (c isp la tin ) has been used fo r 
three decades as an a n ti-ca n ce r tre a tm e n t, b u t is  lim ite d  in  its  
th e ra p e u tic  uses by side effects and ce ll resistance. In  th is  s tudy, new 
c is p la tin  analogues were developed, synthesized, and evaluated fo r 
cy to to x ic ity  and c e llu la r m echanism s. Two novel d rugs 4 ,4 ’-b is (4 ,4 ,4 - 
tr iflu o ro b u ty l)-2 ,2 '-b ip y rid in e  -PtClg and 4 ,4 ’-b is (4 ,4 ,4 -triflu o ro b u ty l)- 
2 ,2 -b ipyrid ine-R e(C O )3 C l and tw o p rev ious ly  synthesized drugs 4 ,4 ’- 
d im e th y l-2 ,2 ’-b ip y rid in e  -PtCU and 4 ,4 ’-d im e th y l-2 ,2 ’-b ip y rid in e - 
Re(CO)sCl were tested, in  b reast cancer ce ll lines M D A -M B -435, M DA- 
M B-231 and transfo rm ed  ce ll lin e s  DC4 and DB46. C y to to x ic ity  assays 
found th a t the  rh e n iu m -co n ta in in g  com pounds had no effect in  the 
transfo rm ed  lin e s  and the  p la tin u m  com pounds were m ore effective th a n  
c isp la tin  a t in d u c in g  ce ll death  in  a ll ce ll lines. F low  cytom etry revealed 
th a t the p la tin u m  com pounds a rre s t ce lls a t a d iffe re n t phase o f the  ce ll 
cycle th a n  c is p la tin . D iffe re n tia l fluo rescen t m icroscopy dem onstra ted
iii
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th a t 4 ,4 ’-b is (4 ,4 ,4 -triflu o ro b u ty l)-2 ,2 ’-b ip y rid in e  -P tC b a n d  4 ,4 ’-d im e th y l- 
2 ,2 ’-b ipyrid ine -P tC l2  induce program m ed ce ll death th ro u g h  apopto tic  
and necro tic  pathw ays.
A p a te n t has been app lied  fo r 4 ,4 ’-b is (4 ,4 ,4  -tr iflu o ro b u ty  1)-2,2’-b ip y rid in e  
-P tC b.
IV
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CHAPTER 1
INTRODUCTION 
C ancer is  caused by a nu m be r o f facto rs , b o th  exte rna l and 
in te rn a l, and is  a category o f disease defined by the  abnorm a l 
p ro life ra tio n  o f ce lls. I t  is  estim ated th a t 1 in  2 A m erican  m en and 1 in  3 
A m erican wom en w ill develop cancer in  th e ir life tim e . The A m erican  
C ancer Society estim ated th a t cancer w ou ld  k ill 563,700 people in  the 
U n ited  S tates in  2004 [1]. C ancer can be trea ted  by a va rie ty  o f m ethods, 
in c lu d in g  surgery, ra d ia tio n , and chem otherapy.
C is -d ia m m ine d ich lo ro p la tinu m  (11) (c isp la tin ) has been in  use fo r 
25 years as a hum an cancer tre a tm e n t fo r a broad va rie ty  o f cancers, b u t 
is  lim ite d  by its  num erous side effects. C isp la tin  is  a DNA a lk y la tin g  
agent f irs t synthesized in  the  1960’s [2]. I t  is  c u rre n tly  used c lin ic a lly  as 
an a n ti-ca n ce r agent and exp erim e n ta lly  as an e ffic ie n t a lk y la tin g  agent. 
I t  was approved by the U.S. Food and D ru g  A d m in is tra tio n  in  1979, fo r 
the  tre a tm e n t o f cancer [3]. C isp la tin  is  m ost com m only used in  the  
tre a tm e n t o f te s tic u la r, n o n -sm a ll ce ll lu n g , ovarian , and head and neck 
cancers. The rem iss ion  ra te  o f c is p la tin  trea ted  te s tic u la r cancer is  over 
90% , w ith  e a rly  stage rem iss ion  a t a lm ost 100% [4].
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C isp la tin  tre a tm e n t has dose lim itin g  side effects in c lu d in g  nausea, 
em etogenesis, h a ir loss, neuropath ies, o to to x ic ity , rena l to x ic ity , and 
p la te le t re d u c tio n . C isp la tin  acts on b o th  cancer ce lls and no rm a l ce lls, 
lead ing to  m ala ise o f p a tie n t and severe side effects. To p ro te c t k idn ey 
fu n c tio n  fro m  the  de le te rious effects o f c isp la tin , p a tie n ts  are 
prescreened fo r re n a l tro u b le s  and i t  is  suggested they d r in k  one 8 ounce 
glass o f w a te r eve iy h o u r w h ile  awake [5]. In  the m ost extrem e cases, 
c is p la tin  has been lin k e d  to  secondary cancers in  p a tie n ts  p rev ious ly  
trea ted w ith  the  d ru g  fo r a p rim a ry  disease. C isp la tin  is  know n to  cause 
chrom osom al breaks and increase crossover o f s is te r ch rom a tids  in  
hum an p e rip h e ra l lym phocytes [6].
The m o le cu la r m echan ism s o f c is p la tin  have been w e ll s tud ied , b u t 
are n o t ye t com plete ly understood . The c is p la tin  isom er trans- 
d ia m m in e d ich lo ro p la tin u m  (11) (tra n sp la tin ) is  c lin ic a lly  ine ffective  in  the 
tre a tm e n t o f cancer. Once in  so lu tio n , the  c is  isom er (c isp la tin ) is  
aquated w ith  the  rep lacem ent o f ch lo rin e s  by w ate r -  Pt(NH 3 )2 (OH 2 )2 .
T h is  a llow s c is p la tin  to  fo rm  adducts w ith  DNA, lip id s , RNA or p ro te in s . 
The 1% o f c is p la tin  fo u n d  in  the  nu c leus w ill b in d  60-65%  a t N7 o f 
guanine in  a GG in tra s tra n d  c ro ss lin k , 25-30%  in tra s tra n d  AG, 5-10%  
in tra s tra n d  1,3-GG and 1-3% in te rs tra n d  GG [7]. These DNA adducts 
are th o u g h t to  be the  p rim a ry  cause o f c is p la tin  cy to to x ic ity . S o lu tio n  
s tru c tu re  o f c is p la tin  bound  DNA dodecam er has show n th a t c is p la tin  
induces a 60-80° bend in  DNA. The bend is  in  the d ire c tio n  o f the  m a jo r
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
groove and causes a w iden ing  o f the  m in o r groove [8]. The p la tin u m  
center o f c is p la tin  can also b in d  in tra c e llu la r p ro te in s , ano ther 
m echanism  o f ce ll death. C isp la tin  adducts  have been fou nd  to  prevent 
ch rom a tin  rem odeling  necessary fo r DNA tra n s c rip tio n , by crea ting  
c isp la tin  D N A -pro te in  c ro ss lin ks  w ith  h is tones [9].
The w iden ing  o f the  m in o r groove o f DNA a lky la te d  by c is p la tin  
a llow s p ro te in s  to  in te ra c t w ith  the  m in o r groove o f the  DNA to  a greater 
extent. Im p o rta n tly , damage recogn ition  p ro te in s , such as the h ig h - 
m o b iliiy  group (HMG) p ro te in s , can recognize the  bend [10]. DNA 
damage induced  by c is p la tin  is  repa ired  th ro u g h  nucleo tide  excis ion  
re p a ir (NER), re com b ina tion  re p a ir, and tra n s le s io n  syn thesis [8]. 
Damage re cogn ition  p ro te in s  have been show n to  b in d  p re fe re n tia lly  to 
c isp la tin  adducts  and b in d  less w ith  o th e r p la tin u m  a lk y la tin g  agents, 
due to  the  bend angle induced  by c is p la tin  adducts  [8]. M ism atch  re p a ir 
(MMR) processes have been show n to increase the  cy to to x ic ity  o f 
c is p la tin , po ss ib ly  due to  dow nstream  s ign a ling  o f apoptosis p ro te in s  [8].
Cancer ce ll resistance to  c is p la tin  can develop from  a nu m be r o f 
m o lecu la r m echanism s. M any cancers are in tr in s ic a lly  re s is ta n t to 
c isp la tin , fo r exam ple 50% o f ova rian  cancer is  re s is ta n t to  c is p la tin  
tre a tm e n t [11]. C isp la tin  resistance has been associated w ith  
overexpression o f m em brane tra n sp o rte rs  th a t are capable o f e fflu x in g  
drugs o u t o f the  cell. One such tra n sp o rte r is  MRP2, a tra n sp o rte r 
im p lica te d  in  m u lti-d ru g  resistance (MDR) phenotypes. O verexpression
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o f MRP2 is  lin k e d  to  in tr in s ic  c is p la tin  resistance [12]. The copper 
tra n sp o rte r, ATP7B, is  a n o th e r overexpressed p ro te in  in  c is p la tin  
re s is ta n t ce lls [13]. M any o th e r cancers develop resistance to  c is p la tin  
over the  course o f tre a tm e n t. A lte red expression o f DNA re p a ir p ro te in s  
has a lso been im p lica te d  in  c is p la tin  resistance. O verexpression o f 
nucleo tide  excis ion  re p a ir p ro te in  E R C C l and fa u lty  m ism a tch  re p a ir 
p ro te in s  have been observed in  c is p la tin  re s is ta n t ce lls  [13 ,14 ]. C olon 
cancer ce ll lines  la ck in g  p53 are sensitive to c isp la tin , suggesting th a t 
p53 expression decreases se n s itiv ity  to  c isp la tin  [16]. Recent s tud ies 
suggest ce ll en v iron m en t can a lte r the  efficacy o f c is p la tin  in  vivo. C ell 
adhesion m ed ia ted-d rug  resistance (CAM-DR), a ce ll adhesion 
m echanism  fou nd  in  m u lti-d ru g  resistance tu m o r ce lls , is  also a fa c to r is 
c is p la tin  resistance [17].
1.1 Novel C om pounds
Due to  the  eas ily  acqu ired  resistance to  c isp la tin , and the 
undes irab le  side effects, the re  is  a con stan t quest fo r new  p la tin u m - 
co n ta in in g  drugs th a t are as effective b u t less cyto tox ic  th a n  c isp la tin . 
P revious w o rk  done by G a re lli, et. a l. described the  syn thesis and 
cy to to x ic ity  o f flu o rin e -c o n ta in in g  b ip y rid y l p la tin u m  com pounds [18].
By add ing  flu o rin e  groups to  the  ta il o f ligands i t  is  th o u g h t the 
b io d is trib u tio n , m echan ism  o f ac tio n  and efficacy can be a lte red. G are lli, 
et. a l. designed and synthesized a series o f com pounds th a t were
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am p h ip a th ic  and cou ld  be inco rpo ra ted  in to  a  liposom e d e live iy  system . 
A ll com pounds in  the  series were b ip y rid y l and had va ry in g  4 /4 ’ 
su b s titu e n ts  (see figu re  1, page 15). The su b s titu e n ts  in c lu d e d  d iffe re n t 
lengths o f m ethylene group spacers between the  rin g  system  and the  
d iffe re n t le n g th  fluo roca rbons. The b ip y rid y l ligands were coord ina ted  to 
e ith e r P tC b o r PdCb [18]. The novel com plexes were inco rpo ra ted  in to  
egg y o lk  phospho lip ids , used as a de live ry m ethod fo r the  d rugs. The 
group had lim ite d  success w ith  in co rp o ra tio n , and had overa ll low  
en trap m en t y ie lds  in to  the  liposom e [19]. Once inco rpo ra ted , G a re lli, et. 
a l. de term ined the  cy to to x ic ity  o f the  com plexes in  liposom es and 
com pared i t  to  the  cy to to x ic ity  o f c isp la tin . They found  th a t the  novel 
com pounds d id  induce ce ll death , b u t were n o t as effective as c isp la tin . 
The p la tin u m  series were less effective th a n  c is p la tin  and exh ib ited  ECso 
num bers 5 to  32 tim es h ig h e r th a n  c is p la tin  [20].
U sing G are lli, et. a l. com plexes as a s ta rtin g  p o in t, a series o f 
com pounds were designed and synthesized th a t cou ld  be used to  tre a t 
cancer ce lls  as e ffective ly as c isp la tin . I t  was o f in te re s t to  synthesize 
novel com pounds th a t ac t s im ila rly  to  c is p la tin , b u t w ith  m o d ifica tio ns  
th a t m ig h t im prove the  e fficacy and reduce the  to x ic ity . F lu o rin e  was 
used p rev iou s ly  by G are lli, and has been used in  m any d ru g  designs 
because flu o rin a te d  com pounds can be inco rpo ra ted  in to  fluo roca rbo n  
de live ry m a te ria ls . F lu o rin a te d  m a te ria ls  are c u rre n tly  being tested as 
oxygen de live ry system s, and have m any a p p lica tio n s  in  d ru g  de livery.
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F luorocarbon  gels, aerosols and w a te r em ulsions are be ing s tud ied  fo r 
d ru g  de live ry  [21], G are lli, et. a l. in d ire c tly  showed th a t fluo roca rbo n  
s u b s titu e n ts  on th e  b ip y rid in e  ligand  do n o t in te rfe re  o r com plete ly 
im pede a c tiv ity  o f the  p la tin u m (ll) center. Based on these fin d in g s , we 
decided to  in c lu d e  flu o rin e  co n ta in in g  su b s titu e n ts  on tw o o f the 
com pounds we synthesized and stud ied .
Previous s tud ies have been com pleted on 2 ,2 ’-d im e th y l-4 ,4 - 
b ip y rid in e -P tC b  as a DNA in te rca la tin g  agent [22]. DNA in te rca la tin g  
agents are p la n a r s tru c tu re s  th a t s lide between the  stacked bases o f 
DNA, in te rru p tin g  the  h e lix . C usum ano, et. a l. showed th a t 2 ,2 ’- 
d im e th y l-4 ,4 ’-b ip y rid in e -P tC b  d id  in te ra c t w ith  DNA by in te rca la tin g . 
O the r s tud ies have looked a t num erous deriva tives o f 2,2 ’-b ip y rid in e - 
P tC b com plexes and th e ir a b ility  to  in te rca la te  in to  DNA [23]. The 
stud ies con firm ed the  in te rca la tio n  o f these com plexes in to  DNA.
The novel com pounds con ta in  the  c is -p la tin u m d ich lo rid e  center, 
w h ich  we propose was used fo r fo rm a tio n  o f adducts  w ith  DNA. They 
also co n ta in  a p la n a r b ip y rid in e  rin g  s tru c tu re , fo r possib le DNA 
in te rca la tio n  [24]. The p la tin u m  cen ter is  bound to  the  n itrogens o f the 
b ip y rid y l system . T a ils  have been a ttached to  the 4 and 4 ’ p o s itio n  on 
the  b ip y rid in e . O n the 4 ,4 ’-d im e th y l-2 ,2 ’-b ipyrid ine -P tC l2  (DM -PtCb) a 
m e thy l g roup has been placed a t the  4 /4 ’ po s ition . O n the  4 ,4 ’-b is(4 ,4 ,4 - 
triflu o ro b u ty l) -2 ,2  ’-b ip y rid in e -P tC b  (R fl-P tC b ) three flu o rin e s  are placed 
on the la s t carbon o f a b u ty l cha in , a t the  4 /4 ’ p o s ition  (See F igure 1,
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page 15). The ligands were also a ttached to  Re(CO)3 Cl. R henium  was 
used to  de te rm ine  i f  the  e fficacy o f the  com pounds was due to  the 
p la tin u m  in te ra c tio n s  w ith  DNA and p ro te in s , o r i f  ano the r m eta l w ou ld  
be as effective and the  e fficacy m ay be due to  the n a tu re  o f the  ligands.
S ynthesis o f the ligan ds was done by classic organom eta llic  
m ethods. 4 ,4 ’-d im e th y l-2 ,2 ’-b ip y rid in e  w as com m ercia lly  ava ilab le  and 
coord inated to  p la tin u m  by d isp lacem ent o f 1,5-cyclooctadiene fro m  1,5- 
cyc loo c tad ie nep la tinu m d ich lo ride  (CO D-PtCb) [25]. D M -P tC b com pound 
had been p rev iou s ly  synthesized and characterized [26]. The 4 ,4 '- 
d im e th y l-2 ,2 ’-b ip y rid in e  lig a n d  has p rev iou s ly  been coord inated by 
reaction  w ith  Re(CO)sCl, the  syn thesis and cha racte riza tio n  was 
p rev ious ly  described [27], R fl-P tC b  is  a novel com pound, the  synthesis 
was adopted from  the m ethods o f G a re lli, e t. a l. [18]. The R fl ligand  was 
also coo rd ina ted  by re a c tio n  w ith  Re(CO)5 Cl. Spectroscopic 
cha rac te riza tio n  o f the  com plexes was done on a 400 M Hz B ru k e r NMR, 
and some com plexes were fu rth e r characte rized by elem enta l ana lys is  a t 
D esert A na ly tics .
1.2 B iochem ica l A p p lica tio n s
Once syn thesis and ch a ra c te riza tio n  were com plete on the 
com pounds, the y were th e n  tested in  v ivo on hum an cancer cells. In itia l 
screenings were done on b reast, lu n g  and tongue cancer ce ll lines. The 
in it ia l assays o f the  com pounds showed the  greatest e fficacy in  b reast
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
cancer ce ll lines. The s tu d y  was then  dedicated to  assaying the  efficacy 
and the  m echanism s o f these com pounds in  b reast cancer.
One in  3 wom en diagnosed w ith  cancer w ill be diagnosed w ith  
b reast cancer, the  m ost com m on fo rm  o f cancer am ong wom en in  the 
U n ited  S tates [1]. M any breast cancers are h o rm o n a lly  responsive, due 
to  the presence o f estrogen receptor (ER+). These receptors have been 
exp lo ited  in  cancer research, w ith  the  te th e rin g  o f p la tin u m  drugs to 
estrogen fo r specific ta rge tin g  o f ER+ cells. H eat Shock p ro te in  27 
(Hsp27) is  a sm a ll heat shock p ro te in . H sp27 fu n c tio n s  as a m o le cu la r 
chaperone p ro te in  and is  fre q u e n tly  overexpressed in  cancers. I t  has 
been suggested th a t H sp27 overexpression can lead to  d ru g  resistance, 
due to  the  a b ility  to  p reven t d rugs from  in d u c in g  ce ll death  [28]. H sp27 
is  responsib le  fo r ce ll m ain tenance, and po lypeptide  re fo ld in g  fo llo w in g  a 
c e llu la r stress. I t  has been show n to  in te ra c t w ith  cytochrom e c, 
released from  m ito ch o n d ria  fo llo w in g  an apoptosis s igna l, and w ith  p ro - 
caspase-3 p reven ting  apop to tic  cascade [29]. H sp27 has been fou nd  to  
p ro te c t ce lls fro m  undergo ing  apoptosis, and has been im p lica te d  in  d rug  
re s is ta n t ce ll phenotypes [30].
C ell death  can occu r th ro u g h  tw o pathw ays -  apoptosis o r 
necrosis. Necrosis is  a fo rm  o f program m ed ce ll dea th , w h ich  occurs due 
to  a c e llu la r tra u m a , u s u a lly  re s u ltin g  in  io n  flu x  changes, sw e lling  o f 
organelles and loss o f in te g rity  o f the  ce ll m em brane. A poptosis, ano ther 
fo rm  o f program m ed ce ll death, is  accom plished th ro u g h  ce ll re g u la to iy
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s ign a ling  pa thw ays and is  energy dependent. A poptosis in itia te s  in  
response to  damage o r s ig n a lin g  m olecules and con tinues th ro u g h  one o f 
the  ap op to tic  pa thw ays (in te rn a l and exte rna l). The in te rn a l ap op to tic  
pa thw ay occurs w ith  the  release o f cytochrom e c from  the  m ito ch o n d ria , 
w h ich  b in d s  apoptosis p ro tease -activa ting  fa c to r 1 (Apaf-1), dATP and 
procaspase-9 to  fo rm  the  apoptosom e. The apoptosom e holoenzym e 
activa tes caspase-9, w h ich  th e n  activa tes caspase-3 in itia tin g  the  
caspase cascade. Caspases activa te  a DNase th a t, in  com b ina tion  w ith  
o th e r p ro te in s , condenses ch ro m a tin  and degrades the  nucleus. The 
exte rna l apoptosis pa thw ay invo lves a ligan d  (i.e. FAS o r TNF) b in d in g  to 
its  recep to r w h ich  activa tes caspase-8, w h ich  then  activa tes the  caspase 
cascade [31]. M orpho log ica l ch a ra c te ris tics  o f apoptosis in c lud e  
m em brane b lebb ing, ch ro m a tin  condensation , cytop lasm  shrinkage  and 
apop to tic  body p ro d u c tio n . The condensation  o f ch ro m a tin , 
fragm en ta tion  o f DNA, and the  flip p in g  o f ph osph a tidy l serine to  the 
e x tra ce llu la r face o f the  m em brane b ila ye r are the ch a ra c te ris tics  used to 
id e n tify  apoptosis in  these s tud ies  [32].
We tested c is p la tin , R fl-P tC b , and D M -P tC b in  fo u r b reast cancer 
ce ll lines , M D A -M B -435, M D A -M B -231, DC4 and D B46. R fl-R e(C O )3 C l 
and DM-Re(CO)3 C l were tested in  DC4 and D B46 ce ll lines. DC4 and 
D B46 are isogenic to  one a n o th e r and are derived from  the  M D A -M B -231 
ce ll lin e . DC4 and D B 46 were m ade by tra n s fe c tio n  w ith  a p la sm id  [33]. 
The p la sm id  in  D B 46 c o n s titu tiv e ly  expresses heat shock p ro te in  27
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(Hsp27) and the  p lasm id  in  DC4 is  the  same as D B 46 w ith  the exception 
o f the  cDNA fo r expression o f H sp27. DC4, M D A -M B -435, and M D A-M B- 
231 a ll express no rm a l levels o f H sp27 [33].
C isp la tin , R fl-P tC b , and D M -P tC b were firs t s tud ied  w ith  
clonogenic su rv iva l assays, in  each o f the  ce ll lines  m entioned above. 
C lonogenic su rv iva l assays were perform ed w ith  R fl -Re(CO]3 C l and DM - 
Re(CO)3 C l in  DC4 and D B46 ce ll lines. These clonogenic assays were 
used to  de term ine the ECso o f each o f the  com pounds in  the ce ll lines. 
The ECso, the effective con cen tra tio n  a t w h ich  50% o f ce lls survive , is  the 
dose m easurem ent used in  these experim ents fo r com parison o f d iffe re n t 
d rugs and ce ll lines . I t  was fou nd  th a t the  novel p la tin u m  co n ta in in g  
com pounds, R fl-P tC b  and D M -P tC b, were m ore effective th a n  c is p la tin  
(i.e. had a low er ECso th a n  c isp la tin ) , w hen app lied  d ire c tly  to  ce ll 
m ed ium , fo r 1 h o u r.
To exam ine the  m echanism s o f ce ll death, flow  cytom etry  was used 
to  assess bo th  ce ll cycle in h ib itio n  and apoptosis in d u c tio n . The 
e u ka ryo tic  ce ll cycle is  d iv ided  in to  tw o p a rts  and fo u r phases. The firs t 
p a rt is  in te rphase  and inc lud es G i, S and Gs. The second p a rt is  m ito s is  
and inc lud es M phase. Gap 1 phase (G i) is  characte rized by tra n s c rip tio n  
and tra n s la tio n  in  p repa ra tio n  fo r DNA synthesis. S ynthesis phase (S) is 
w hen DNA syn thesis occurs and a com plete copy o f the  genome is  m ade. 
Gap 2 phase (Gs) is  characterized by co n tin u e d  g row th  o f the  ce ll, 
re p lica tio n  o f th e  organelles and p re p a ra tio n  fo r m ito s is . M ito tic  phase
10
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(M) is  a w e ll characte rized  stage th a t invo lves the d iv is io n  o f the  ce ll in to  
tw o id e n tic a l da ugh te r ce lls. N on -d iv id ing  ce lls are said to be in  Go 
phase. The ce ll cycle is  p recise ly con tro lle d  by ce llu la r s igna ling  
pathw ays. C yc lin  dependent k inases (CDKs), cyc lins and o th e r p ro te in s  
co n tro l the  progression fro m  one phase o f the  cycle to  th e  ne xt [34]. 
C isp la tin  has p rev iou s ly  been fou nd  to  induce a ce ll cycle b lock.
However, the  b lo ck  is  n o t a lw ays con s is ten t and appears to  be ce ll lin e  
dependent [10]. I t  has p re v io u s ly  been suggested th a t an S/G a b lo ck  is  
necessary fo r re p a ir o f DNA a fte r c is p la tin  tre a tm e n t, before m ito s is  
begins [35].
To de te rm ine  w here the  ce ll cycle b lock occurs in  c is p la tin , R fl-  
P tC b and D M -P tC b, in  each ce ll lin e , p ro p id iu m  iod ide (PI) s ta in in g  was 
used and m easured w ith  flow  cytom etry. F low  cytom etry is  an 
au tom ated m ethod developed to  observe fluorescence w ith in  a single 
d rop le t co n ta in in g  a sing le  ce ll. PI is  a DNA s ta in  th a t was used to  
determ ine i f  the  ce ll cycle in h ib itio n  occurs a t s im ila r phases fo r each 
drug , and i f  th is  suggests a s im ila r m echanism  o f a c tio n  between the  
drugs. P rop id ium  Iod ide (PI) is  know n to  be active ly  excluded fro m  in ta c t 
liv in g  ce lls, and take n  u p  by ce lls w ith  com prom ised c e llu la r m em branes. 
Once take n  u p  in to  the  ce ll PI w ill in te rca la te  in to  DNA. The fluorescence 
can be m easured by flo w  cytom etry  (exc ita tion  488 nm , em ission 600 
nm ) [36]. The in te n s ity  o f fluorescence is  corre la ted to  the  a m o u n t o f 
DNA, in  the  ce ll. F rom  th is , the  flow  cytom eter can de term ine a t w h ich
11
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p o in t o f the ce ll cycle the ce ll is  in . S u b -G i/A p o p to tic  cells are found  due 
to  the  nuc lea r and DNA fra gm e n ta tion  th a t occurs d u rin g  apoptosis. The 
fragm ented DNA w ill appear as less th a n  the  com plete genome and w ill 
fluoresce accord ing ly. S ynchronized ce ll s tud ies w ith  PI ind ica te  th a t 
c isp la tin , R fl-P tC b  and D M -P tC b act by in h ib itin g  ce ll cycle progression 
a t d iffe re n t po in ts .
A nnexin  V  s ta in in g  was used w ith  flow  cytom etry  to de term ine i f  
apoptosis is  induced in  the  ce lls w hen exposed to  the  d iffe re n t d rugs [37]. 
A nnexin  V  b in ds  to  p h o sp h a tid y l serine, a n a tu ra lly  o ccu rrin g  c e llu la r 
ph osph o lip id  bound  to  the  in n e r m em brane o f ce lls. In  uncom prom ised 
cells, A nnexin  V  is  excluded fro m  the  ce ll and w ill n o t b in d  p h o sp h a tid y l 
serine. Once a ce ll has been signaled to  undergo apoptosis, an ea rly  
event is  the  flip p in g  o f p h o sp h a tid y l serine to  the  ou ts ide  o f the  ce ll 
m em brane. Once ou ts ide  the  ce ll m em brane, exogenously app lied  
A nnexin  V  w ill b in d  the p h o sp h a tid y l serine. The fluorescence o f the  
FITC labe l on A nnexin  V  can be m on ito red  by flow  cytom etry  (exc ita tion  
488 nm , em ission 535 nm ) [37]. A nne x in  V  s ta in in g  is  done 
s im u lta n e o u s ly  w ith  PI s ta in in g  to  de term ine the  in te g rity  o f the 
m em brane. I f  the  in te g rity  o f the  m em brane is  com prom ised th is  can be 
seen by the  fluorescence o f the  PI bound  to  DNA. We fou nd  th a t 
c is p la tin , R fl-P tC b  and D M -P tC b induced  apoptosis in  the b reast cancer 
ce ll lines.
12
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
F luorescen t m icroscopy was used to  co n firm  the  re s u lts  o f the  
clonogenic su rv iva l assays and the  flow  cytom etry  stud ies. S pecific 
s ta in in g  was used to  v is u a lly  de term ine the  m echanism  o f ce ll death  in  
the  ce lls. H oechst s ta in in g  was used to  b in d  DNA, and view  ch ro m a tin  
condensation , an ea rly  event in  apoptosis. Hoechst (e xc ita tion  346 nm , 
em ission 460nm ) is  re a d ily  taken  u p  by ce lls, b u t ac tive ly  pum ped o u t o f 
h e a lth y  live  ce lls [38]. H oechst is  on ly  taken  up  in to  ce lls  w ith  d e fic ie n t 
p u m p in g  system s, i.e. ea rly  apop to tic  ce lls. PI was also used to  s ta in  
DNA; ty p ic a lly  PI is  excluded from  h e a lth y  live  cells and is  o n ly  able to 
en ter a ce ll and s ta in  DNA w hen the  in te g rity  o f the  ce ll m em brane has 
been com prom ised.
These s tud ies fo u n d  R fl-P tC b  and D M -P tC b to  have a la rg e r effect 
th a n  c is p la tin  a t eq u iva le n t doses. C lonogenic su rv iva l da ta  showed bo th  
R fl-P tC b  and D M -P tC b to  have low er ECso values th a n  c is p la tin . F low  
cytom etry  showed c is p la tin , R fl-P tC b  and D M -P tC b in h ib it the  ce ll cycle 
a t d iffe re n t p o in ts . F low  cytom etry  and fluo rescen t m icroscopy showed 
th a t c is p la tin , R fl-P tC b  and D M -P tC b induced  bo th  apoptosis and 
necrosis. R fl-P tC b  and D M -P tC b induced  apoptosis and necrosis to  a 
greater ex te n t th a n  d id  c isp la tin .
1.3 H ypothesis
A novel series o f p la tin u m d ich lo rid e  com pounds, co n ta in in g  a 
b ip y rid y l system  w ith  ta ils  a t the  4 and 4 ’ pos itions  w ill be as effective
13
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and act in  a m anner s im ila r to  c is p la tin . S im ila r ligands coord inated to  
rh e n iu m , w ill n o t ac t in  a m anner s im ila r to  c isp la tin .
14
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C om pounds Used
H3N. .NH3
cr Cl
Cis-diamminedichlorplatinum(II)
cisplatin
CF.
4,4'-bis(4,4,4-trifluorobutyl)-2,2'-bipyridine-PtCl2
Rfl-PtCla
5
4,4 ’-dimethyl 2,2'-bipyridine-PtClg 
DM-PtCla
CF.
oc
oc
OC^-Re Cl
OC \ :o
4,4'-bis(4,4,4-trifluorobutyl)-2,2''bipyridine-Re(CO)3Cl 4,4'-dimethyI 2,2'-bipyridine-Re(CO)3CI 
Rfl-Re(CO)3 Cl DM-Re(CO)3 Cl
Figure 1 C om pounds used in  the  experim ents. C isp la tin  is  c u rre n tly  in  
use c lin ic a lly  as an  a n ti-ca n ce r tre a tm e n t. R fl-P tC b , D M -P tC b, R fl-  
Re(CO)3 C l and DM-Re(CO)3 C l were com pounds synthesized, 
characte rized  and assayed.
15
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CHAPTER 2
MATERIALS AND METHODS
2.1 O rganic S ynthesis M a te ria ls  and  M ethods
2.1.1 C hem icals
1,5-C yclooctadiene p la tin u m  d ich lo rid e  was prepared as described 
by C la rk , et. a l. [25]. 4 ,4 -d im e th y l-2 ,2 ’-b ip y rid in e  -P tC b was prepared 
as described by B ie lli, et. a l. [26]. 4 ,4 ’-TH F was d is tille d  from  
benzophenone/S od ium . KgPtCH, Re(CO)sCl, d ie th y l e ther, m ethano l, 
Na2S04, n -p ropano l, S nC b, 1,5-cyclooctadiene, 4 ,4 ’-d im e th y l-2 ,2 ’- 
b ip y rid in e , e thano l, benzene, to luene , a ce to n itrile , and h yd ro ch lo ric  acid 
were used as received fro m  the  m a nu fa c tu re r.
2 .1 .2  Synthesis
4 ,4 ’-b is (4 ,4 ,4 -tr iflu o ro b u ty l)-2 ,2 ’-b ip y rid in e  ligand  (R fl) was synthesized 
as fo llow s -  2 .48 g (24.5 m m oles) o f d iisop ropy lam ine  was added to  100 
m L o f d iy  THF in  a 250 m L ro u n d  b o ttom  fla sk , w ith  the  head space 
rem oved and replaced w ith  n itro g e n  gas. The so lu tio n  was placed in  a 
so lid  CO2 /ace tone b a th  (-78°C) and 21 .5  m m oles o f n -b u ty llith iu m  in  
hexanes (2.541 M) was added v ia  syringe (over 5 m in u te  period). The 
so lu tio n  was s tirre d  fo r 20 m in u te s  a t -78°C , rem oved and s tirre d  fo r 30 
m inu tes  a t 0°C (in  an ice w a te r ba th ), and re tu rn e d  to  -78°C  and s tirre d
16
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fo r 20 m inu tes. 19.9 g (10.8 mmoles) o f 4 ,4 ’-d im e th y l-2 ,2 ’-b ipy rid ine  
was dissolved in  20 m L o f d ry  THF, w ith  the  head space removed 4 tim es 
and replaced w ith  n itrogen gas. The 4 ,4 ’-d im e th y l-2 ,2 ’-b ip y rid in e  
so lu tion  was added to reaction  flask  a t -78°C via syringe and  s tirred  fo r 3 
hours. 52 .6  g (22.1 mmoles) o f 3 ,3 ,3 - tr if lu o ro -1 -iodopropane was 
dissolved in  50 m L o f d ry  THF and ra p id ly  added to reaction  flask, v ia 
syringe. S o lu tion  was allowed to  s tir  and come to  am b ien t tem perature  
overn ight. S o lu tion  was quenched w ith  140 m L o f b rine-ice  w a te r and 
extracted 3 tim es w ith  75 m L po rtions  o f d ie thy l ether. D ie th y l e ther 
extracts were d ried  over NazS0 4  and e ther was evaporated from  product, 
a ffo rd ing  b row n crysta ls. P roduct was rec iys ta llized  in  w a rm  m ethanol, 
a ffo rd ing  1.527 g (4.057 m m oles, 37.5%  yield), (see Figure 2, page 25). 
P recip itate was analyzed by  NMR.
4 ,4 ’-b is (4 ,4 ,4 -tiif lu o ro b u ty l)-2 ,2 ’-b ip y rid in e  -P tC b was synthesized as 
follows -3 8 .0  m g (0.094 mmoles) (l,5-CO D)PtC l2, 0.104 m m oles (38.9 
mg) 4 ,4 ’-CF3(CH2)s-2,2 ’-b ip y rid in e , and 15 m L  o f ace ton itrile  were added 
to 100 m L ro u nd  bo ttom  flask. The m ix tu re  was re fluxed fo r 
approx im ate ly  24 hours. Upon cooling the  solvent was evaporated and 
CO D-PtCb removed v ia  vacuum . The residue was then  dissolved in  
ace ton itrile  and p rod u c t p rec ip ita ted  w ith  d ie thy l ether. The ye llow  solid 
was iso la ted by f iltra tio n , a ffo rd ing  37 m g (0.0467 mmoles, 61%  yield)
(see figu re  3, page 25). P recip ita te was analyzed by NMR.
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4,4 -d im e th y l-2 , 2 b ip y rid ine  -P tC b was synthesized as follows -  15 m L  o f 
a IM  HCl so lu tion  was added to 60.0 mg (0.32 mmol) 4 ,4 -d im e th y l-2 ,2 ’- 
b ipy rid ine  and the s tirre d  to dissolve, w ith  atm osphere replaced w ith  Ng. 
132 mg (0.32 m m ol) KgPtCh was dissolved in  5 m L deionized H 2 O and 
added slow ly to 4,4 -d im e th y l-2 ,2 ’-b ip y rid in e  so lu tion  v ia  syringe. The 
m ix tu re  was allowed to s t ir  fo r 24 hours , then  filte red  and rinsed w ith  
H 2 O, a ffo rd ing  a ye llow  solid  (see F igure 4, page 25). Precip itate was 
analyzed by NMR.
/a c -4 ,4 ’-b is (4 ,4 ,4 -tr iflu o ro b u ty l)-2 ,2 ’-b ipy rid ine  - Re(CO)3 Cl was 
synthesized as fo llows -4 9 .0  m g (0.266 mm ol) 4 ,4 ’-b is(4,4 ,4- 
tr ifiu o ro b u ty l) -2 ,2 ’-b ip y rid in e  ligand  was added to a 50 m L round  bo ttom  
flask  w ith  98 m g (0.271 m m ol) Re(CO)5 Cl. A pprox im ate ly  18-20 m L o f 
to luene was added and the so lu tion  was re fluxed fo r 2 hours  and then  
allowed to come to am b ien t tem perature. P recip itate was filte red  and 
collected, a ffo rd ing  95 m g (0.139 m m ol; 52.4%  yield) (see figure 5, page 
25). P recip itate was analyzed by NMR, and E lem ental Analysis. 
/a c -4 ,4 ’-d im e th y l-2 ,2 ’-bipyridine-Re(CO)3Cl was synthesized as fo llows -  
0.2g (1.085 mmoles) 4 ,4 ’-d im e th y l-2 ,2 ’-b ip y rid in e  and 0.672g (1.86 
mmoles) o f Re(CO)sCl were com bined in  a 250 m l flask. Then, 50 m L o f 
benzene was added, and so lu tion  was allowed to re flu x  fo r 4 hours. 
So lu tion  was filte red  over vacuum  and ye llow  solid collected fo r analysis, 
a ffo rd ing 461 mg (0.9408m m oles, 86.7%), (see figure 6, page 25). 
P recip itate was analyzed by NMR.
18
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
2.1.3 C haracte riza tion
NMR spectra were obta ined us in g  a B ru k e r AM X 400 spectrom eter a t 
298 K o r 320 K: iH , 400 MHz; i^C, 100.65 MHz; 376.477 MHz. 
E lem enta l A na lys is  was perform ed by Desert A na ly tics  (Tucson, AZ).
2.2 B iochem is try  M ateria ls  and Methods
2.2.1 Tissue C u ltu re
Four breast cancer ce ll lines were used -  DC4, DB46, M DA-M B- 
435 and M D A-M B-231. M DA-M B-231 (ATCC num be r HTB-26), breast 
ep ithe lia l adenocarcinom a, cell line  was obta ined from  A m erican Type 
C u ltu re  C ollection. M D A-M B-435 (ATCC nu m be r HTB-129), breast 
duc ta l adenocarcinom a, cell line was ob ta ined from  A m erican Type 
C u ltu re  Collection. DC4 and DB46 were derived from  M D A-M B-231, as 
described by Carper, et. al. [33]. DB46 con ta ins vector p^27  w ith  the 
Hsp27 cDNA un de r the con tro l o f p ac tin  p rom oter and neom ycin 
res is tan t gene u n de r the con tro l o f s im ian  v iru s  early  prom oter. DC4 
con ta ins vector pAP-APRl-neo w ith o u t any Hsp27 cDNA and expresses 
endogenous levels o f Hsp27. A ll cell lines were grow n in  M in im u m  
Essentia l M edium  (MEM) w ith  L -g lu tam ine , and E arle ’s salts, 
supplem ented w ith  10% Fetal Bovine Serum , 50m M  Hepes (pH 7.4), 100 
U /m L  p e n ic illin  and 100 U /m L  streptom ycin . The a n tib io tic  G418 (75 
pL o f a 40 p g /m L  solu tion) was ad justed  to a fin a l vo lum e o f 5.0 m L w ith  
supplem ented MEM  added to DC4 and D B46 cell lines, fo r p lasm id
19
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m aintenance. Phosphate Buffered Saline (PBS) pH 7.2 was used to  wash 
cells and T iy p s in  (0.25% w ith  EDTA-4Na 0.38 g /L ) was used to 
chem ica lly  detach adheren t cells. Cells were grown in  37°C in cu ba to r, 
w ith  5% CO2 . A ll cell c u ltu re  m ateria ls  were purchased from  Inv itrogen, 
un less otherw ise noted.
2.2.2 Chem icals
C is -P la tinum (ll)-D iam m ine  D ich lo ride  (cisplatin) was purchased 
from  Sigma. 4 ,4 ’-b is (4 ,4 ,4 -tr iflu o ro b u ty l)-2 ,2 ’-b ipy rid ine  -P tC b [R fl-  
P tCb], 4 ,4 ’-d im e th y l-2 ,2 ’-b ip y rid in e  -P tCb [DM -PtCb], 4 ,4 ’-b is(4 ,4 ,4- 
tr if lu o ro b u ty l)-2 ,2 ’-b ip y rid in e  -Re(CO)sCl [R fl-Re(CO)3 Cl] and 4 ,4 ’- 
d im e th y l-2 ,2 ’-bipyridine-Re(CO)3Cl [DM-Re(CO)3 Cl] were synthesized as 
described previously, section 2.1 .2. A ll drugs were so lub ilized in  f ilte r  
sterilized DMSO to appropria te  concentra tions. A ll reagents and enzymes 
were o f ana ly tica l grade from  Sigma except where otherw ise stated.
2.2.3 Clonogenic S urv iva l Assay
DC4 and DB46 were p la ted 2 days p r io r to experim ent w ith o u t 
G418. Cells were exposed to  chem icals fo r 1 h o u r a t 37°C a t 5% CO 2 , 
d u rin g  exponentia l g row th  phase. A fte r 1 h o u r the  m edia and drugs 
were removed, cells were washed once w ith  PBS pH 7.2 (PBS), cleaved 
from  flask w ith  tryp s in  fo r 3-10 m inu tes, and resuspended in  
supplem ented M EM . Cells were counted us ing  B eckm an C ou lte r Z1 
Particle Counter. A ppropria te  nu m be r o f cells were p la ted in  60m m  cell 
cu ltu re  d ish  w ith  5m L supplem ented MEM. Cells were incubated  fo r 11-
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14 days, a fte r w h ich  the m edia was removed, and cells were sta ined w ith  
0.5% crys ta l v io le t in  95% ethanol. Colonies con ta in ing  more th a n  50 
cells were counted m anua lly . A ll num bers  reported are norm alized to the 
contro l.
2.2.4 Flow C ytom etry
Forty-e igh t ho u rs  before the experim ent cells, were harvested and 
replated in to  flasks. A fte r 24 hours , m ed ium  was replaced w ith  
supplem ented M EM w ith o u t fe ta l bovine serum  and ap h id ico lin  was 
added (to synchronize the cells) a t a fin a l concentra tion  o f 1 pg /m L .
Cells were incubated  a t 37°C and 5% CO 2  fo r 24 hours. A fte r 24 hours, 
m ed ium  was removed and replaced w ith  supplem ented MEM  and treated 
w ith  appropria te  concentra tion  o f c isp la tin , R fl-P tC b  or D M -P tC b fo r 1 
hour. Cells were collected a t appropria te  tim es fo r analysis by flow  
cytom etry  and PI s ta in ing.
For p rop id iu m  iodide s ta in ing , cells were treated in  the  exponentia l 
phase o f g row th w ith  appropria te  chem ical fo r 1 h o u r a t 37°C and 5% 
CO2 . A t appropria te  tim es (12, 24, 48 and 72 hours) cells were 
harvested, counted and centrifuged a t 400 x  g fo r 5 m inu tes. A fte r 
pou rin g  o ff the m edium , cells were resuspended in  5m L PBS and 
centrifuged a t 400 x  g fo r 5 m inu tes. The PBS was poured off, eells were 
resuspended in  0.1 m L PBS and Im L  o f -20°C 70% ethano l was added 
dropw ise w h ile  gently  vortexing. Cells were stored a t 4°C u n t i l  analyzed. 
For ana lysis, e thano l-fixed cells were cleared o f excess e thano l by a
21
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single w ash w ith  3 -5 m l o f cold PBS a t 500 X  g fo r 5 m inu tes. The pe lle t 
was resuspended w ith  100 pL o f 0.1%  T rito n  X -100 and gently vortexed. 
RNase (100 pL o f 1.0 m g /m L  solu tion) was added and the m ix tu re  
incuba ted  a t room  tem perature fo r 10-15 m inu tes before s ta in ing , in  the 
da rk , w ith  200 pL o f 100 p g /m L  PI so lu tion  (BD Biosciences 
Pharm ingen). F in a l PI concentra tion  in  the 400 pL test m ix tu re  is  50 
pg /m L . C y tom e tiy  acqu is ition  was done on Becton D ick inson  FACS 
C a lib u r w ith  argon laser set a t 488nm  on the linea r Flow C hanne l 2 (FL- 
2) w ith  D oub le t D isc rim in a to iy  M odule (DDM) set on FL-2. D ata was 
collected u s in g  CellQ uest version 3.0 software (Becton D ick inson  
Im m un o cy to m e tiy  Systems F ra n k lin  Lakes, NJ).
For A nnex in  V /P l s ta in ing , cells were treated w ith  appropria te  d rug  
d u rin g  exponentia l phase o f g row th fo r 1 h o u r a t 37°C a t 5% CO 2 . Cells 
were harvested, counted, and centrifuged a t 400 X  g fo r 5 m inu tes. The 
m edia was removed; cells were re suspended in  m edia and cen trifuged fo r 
5 m inu tes  a t 400 X  g. M edium  was removed and cells were harvested 
and washed in  1.0 m L PBS (Ca^+ and Mg^+ free). The num bers o f cells 
were ad justed to  approx. 500,000 cells per m L before pe lle ting  a t 400 X  g 
fo r 5 m inu tes. The pelle ts were then  washed in  2.0 m L x l  A nnex in -V  
B ind in g  B u ffe r (BD Biosciences Pharm ingen) and centrifuged a t 500 x  g 
fo r 5 m inu tes. The pelle ts were treated w ith  Annexin-V -F ITC  conjugate 
(BD Biosciences Pharm ingen) and incuba ted  in  the  d a rk  fo r 15 m inu tes, 
a t room tem perature . The treated m ix tu re  conta ined 5 pL o f con jugate to
22
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approx im ate ly  500,000 cells in  the presence o f 1 pL Fetal Bovine Serum. 
J u s t before acqu is ition , the volum e o f eells-conjugate m ix tu re  was 
ad justed u p  w ith  ad d ition  o f 450 pL o f I x  A nnex in -V  b in d in g  buffer,
(each tube con ta ins ce lls-conjugate m ix tu re  o f approx. 500 pL). To 
d iscrim ina te  between apoptotie  and necro tic  cells, cells-conjugate 
m ix tu re  was counte rsta ined w ith  10 pL PI (50 pg/m L) so lu tion  (BD 
Bioscience Pharm ingen). A cqu is itions  were done on B D ’s FACS C a libu r 
Cytom eter on the F L l (Annexin) and FL3 (PI) channels on FSC and 
D oub le t D isc rim in a tin g  M odule (DDM) set a t F L l.  The level o f sh ift in  
events d is tr ib u tio n  in  the  treated cells s ta ined w ith  A nnex in  V  on ly  and 
A nnexin  V /P l popu la tions in  com parison to  un trea ted  con tro ls  is 
ind ica tive  o f the degree o f effectiveness o f the  trea tm ent agent(s).
N um eric quan tiza tion  o f these events sh ifts  are accom plished w ith  
popu la tion  gating, set accord ing to 100 % o f the con tro l and applied to 
trea tm en t groups.
2.2.5 F luorescent M icroscopy
T w enty-fou r hou rs  before exposure to chem icals, cells were 
harvested and counted (as described above). Ten thousand  cells per w ell 
were placed in  Lab-Tek II 4 w e ll cham ber slide w ith  cover (Lab-Tek 
N aperville, XL) w ith  vo lu m e ad ju sted  to O.SmL u s in g  su p p lem en ted  MEM. 
Cells were exposed to appropria te  concentra tion  o f d rug  fo r 1 h o u r a t 
37°C, 5% CO 2 . A fte r 1 h o u r d rug  was removed, eells were rinsed  w ith  
0.5m L PBS and 0 .5m L supplem ented M EM  was added. A t appropria te
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tim es, m ed ium  was removed and replaced w ith  O.SmL so lu tion  o f 
lO fig /m L  P rop id ium  Iodide (BD Biosciences Pharm ingen) and 2 p g /m L  
Hoechst 33342 (Sigma) in  PBS,. The eells were incu ba ted  in  the  d a rk  a t 
room  tem pera tu re  fo r 15 m inu tes, then  viewed th ro u g h  a N ikon Eclipse 
m icroscope, m odel TE2000-U  (Lake Forest, C aliforn ia). W ith  PI s ta in ing , 
a bandpass exc ita tion  f ilte r  w ith  wavelength 560-580 nanom eters was 
used and w ith  Hoechst s ta in  a bandpass exc ita tion  f ilte r  w ith  wavelength 
395-410 nanom eters was used. Cells were imaged w ith in  5 m inu tes  
fo llow ing the 15-m inu te  s ta in ing . S tained cells were counted m anua lly , 
and norm alized to  the contro l.
2 .2 .6  S ta tis tica l Analysis
A nalys is o f flow  cy tom e tiy  on PI sta ined cells was done us ing  
M odF it version 3.0 program . JM P s ta tis tica l analysis software version 
5.0.1 (SAS Cary, NC) was used to ru n  S tud en t’s t-tes ts , ANOVA, and 
Tukey tests. G raph Pad Prism  4 (Graph Pad Software San Diego, CA) 
was used to  ru n  no n -line a r regressions, curve f it t in g  and fo r g raph ing  o f 
data.
24
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S ynthetic  Schemes
F3C(H2C)3 (CH2)3CF3
= \  / = : \  1) 2 eq. n-butyllithium -78°C THF
 ^
2) 2 eq. I-(CH2 )3 CF3N N-
Figure 2 S ynthetic  Scheme o f 4 ,4 -b is(4 ,4 ,4 -trifluo robu1y l)-2 ,2 -b ip y rid in e  
ligand.
F3C(HgC)3 (CHg)3CF3
L IV  Cl
N N
F3C(H2C)3 (CH2)3CF3
A MeCN N N
Figure 3 S ynthetic  Scheme o f 4,4 - h i s (4,4,4 - tr iflu o ro b u ty l) - 2,2 
b ip y rid ine -P tC b .
K2PtCl2
-N N- IM  H Cl N N
Figure 4 Synthetie  Seheme o f 4 ,4 -d im e th y l-2 ,2 -b ipyrid ine -P tC h .
FsCIHgCja
N N
(CHglsCFs
RelCOIgCl
F3C(H2C)3 (CHalsCFs
ytoluene v— — (/
O C ^ F e - - - C l
OC CO
Figure 5 S ynthetic  Scheme o f/a c -4 ,4 ’-b is (4 ,4 ,4 -tr iflu o ro bu ty l)-2 ,2 ’- 
b ipyridine-Re(CO )3 CL
Re(CO)gCl
-N N -^  ^
OC^^PG— Cl
oc CO
Figure 6 S ynthe tic  Scheme fo r yhc-4,4 '-d im e th y l-2 ,2 '-b ipyrid ine - 
Re(CO)3 Cl.
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CHAPTER 3 
RESULTS
3.1 O rganic Synthesis Results
4 ,4 ’-b is (4 ,4 ,4 -trifluo robu1y l)-2 ,2 ’-b ip y rid in e  ligand [R fl ligand]
A na ly tica l ca lcu la ted fo r CigHisFeNg: C 57.45, H 4.82, N 7.44. Measured: 
C 57.73, H 4.74, N 7.53.
NMR: m  (400 MHz, 298 K, CDCI3 ) Ô 8.62 (d, 3Jhh = 5.0 Hz, 2H, C-H, 
6 /6 3  8.28 (d,4JHH = 1.0 Hz, 2H, C-H, 3 /3 3  7.17 (d,d 3Jhh = 5.0 Hz, Mhh 
= 1.0 Hz 2H, C-H, 5 / 5 3  2.81 (t, s jan  = 7.7 Hz, 4H, CF3 CH 2 CH 2 CH 2 -Ar) 
2.14 (m ,4H , CF3 CH 2 CH 2 CH 2 -Ar) 2.01 (m ,4H , CF3 CH 2 C fb C H 2 -Ar); 
i3C{iH} (100.65 MHz, 298 K, CDCI3 ) 6 156.45 (20, 2 / 2 ’) 150.87 (20, 4 /4 3  
149.50 (20, 6 /6 3  126.9 (q, V rc  = 276 Hz, 2 0 , CF30H20H20H2-Ar) 123.97 
(20, 3 / 3 3  121.33 (20, 5 / 5 3  34.35 (20, 0 F3 0 H 2 0 H 2 CH2 -Ar) 33 .30 (q,
2Jfc = 29 Hz, 2 0 , 0F3Œ 20H20H2-Ar) 22 .73 (20, 0F30H2CH20H2-Ar); 
(376.47 MHz, 298 K, ODOI3) 6 -71.17 (t, 6F, 3Jhf=10 H z) [39]. See 
A ppend ix  1, page 70.
4 ,4 ’-b is (4 ,4 ,4 -tr if lu o r o b u ty l)-2 ,2 -b ip y r id in e  -P tC b  [R fl-P tC b ]
A na ly tica l ca lcu la ted fo r 0i8Hi80bF6N2Pt: O 33.66, H 2.82, N 4.36. 
Measured: O 33.81, H 2.80, N 4.25.
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NMR ; (400 MHz, 295 K, acetone-de) 6 9 .555 (d, 3J hh = 5.8 Hz, 2H, -
CH, 6 / 6 ) ,  8 .474 (s, 2H, -CH, 3 / 3 ) ,  7.739 (d, 3Jhh = 5.3Hz, 2H, -CH,
5 /53 , 3.3 (t, 3Jhh = 7.8 Hz, 4H, CFsCHgCHgCfb-Ar), 2.85 (m, 4H, - 
CH 2 CH 2 CH 2 CF3 ), 2 .375 (m, 4H, -CH 2 CH 2 CH 2 CF3 ); (100.65 MHz,
298 K, acetone-de) Ô 158.72 (2C, 2 / 2 )  156.85 (2C, 4 /4 3  149.87 (2C,
6 /6 3  128.84 (q, iJ fc  = 291.7 Hz, 2C, CF3 CH 2 CH 2 CH 2 -Ar) 128.83 (2C,
3 / 3 3  125.98 (2C, 5 / 5 3  35.71 (2C, CF3 CH 2 CH 2 Œ 2 -Ar) 34.48 (q, 2Jfc = 
29 Hz, 2C, CF3 CH2 CH 2 CH 2 -Ar) 23.55 (2C, CF3 CH 2 Œ 2 CH 2 -Ar);
(376.47 MHz, 298 K, acetone-de) 6 -66.54 (t, 6F, 3J hf = 11.5 Hz). See 
Append ix I, page 70.
4 ,4 ’-d im e th y l-2 ,2 ’-b ip y rid in e  -P tCb [DM -PtCb]
NMR: iH  (400 MHz, 320 K, DMSO-de) 6 9.28 (d, 3Jhh = 5.8 Hz, 2H , C-H, 
6 / 6 )  8.39 (s, 2H, C-H, 3 / 3 )  7 .65 (d 3Jhh = 5.3 Hz, 2H, C-H, 5 / 5 )  2.5 (s, 
3H, C fb -A r); i3C{iH} (100.65 MHz, 320 K, DMSO-de) ô 156.02 (20, 2 / 2 )  
152.27 (20, 4 / 4 3  147.30 (20, 6 /6 3  127.70 (20, 3 /3 3  124.40 (20, 5 /5 3  
20.84 (30 CHs-Ar). See A ppend ix  I, page 70.
4 ,4 ’-b is (4 ,4 ,4 -tr iflu o ro b u ty l)-2 ,2 ’-b ip y rid in e  - Re(00)301 [R fl-R e(0 O)3 0 1 ] 
A na ly tica l ca lcu la ted fo r O2 1Hi801F6N203Re: O 36.98, H 2.66, N 4.11. 
Measured: O 37.16, H 2.68, N 4.06.
NMR: iR  (400 MHz, 298 K, CDCI3 ) 6 8.974 (d, 3Jhh = 5 Hz, 2H, C-H, 
6 / 6 )  7 .520 (s, 2H, C-H, 3 / 3 )  7 .375 (d Mhh = 5 Hz, 2H, C-H, 5 /5 3  2.923 
(t, 3Jhh = 8.0 Hz, 4H, 0 F3 0 H 2 0 H 2 0 H 2 -Ar) 2 .236 (m, 4H, 0 F3 0 f b 0 H 2 0 H 2 - 
Ar) 2 .038 (m, 4H, 0 F3 0 H 2 0 f b 0 H 2 -Ar); i ^ q ih }  (100.62 MHz, 298 K,
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CDCls) ô 197.06 (2C, 00-Re) 189.51 (1C, 00-Re) 155.72 (20, 2 /2 3  
153.69 (20, 4 /4 3  153.11 (20, 6 /6 3  128.02 (q, U fc  = 276 Hz, 20 , 
CFsOHgOHgOHz-Ar) 127.04 (20, 3 /3 3  122.93 (20, 5 /5 3  34.22 (20, 
OFsOHaOHaOHa-Ar) 33.23 (q, ^Jfc = 28.9 Hz, 20 , 0F3CH20H20H2-Ar) 
22.42 (20, 0 F3 0 H 2 CH2 0 H 2 -Ar); (376.47 MHz, 298 K, ODOI3) 6 -71.2
(t, 6F, 3J hf = 1 0  Hz) See A ppend ix  I, page 70.
4 ,4 -d im e th y l-2 ,2 ’-b ipyrid ine-R e(0 O ) 3 0 1  [DM-Re(0 0 )3 0 1 ]
NMR: iH  (400 MHz, 320 K, ODOI3) 6 8 .88 (d, 3Jhh = 5.0 Hz, 2H, C-H, 
6 /6 3  7.94 (s, 2H, C-H, 3 / 3 )  7.31 (d 3Jhh = 4.4 Hz, 2H, C-H, 5 / 5 )  2.55 (s, 
3H, CHs-Ar) ; i3C{iH} (100.65 MHz, 320 K, ODOI3) ô 200.55 (20, OO-Re) 
197.61 (10, OO-Re) 156.02 (20, 2 / 2 )  152.96 (20, 4 /4 3  151.41 (20, 6 /6 3  
128.34 (20, 3 / 3 3  124.07 (20, 5 /5 3  21.99 (30, CH3 -Ar). See A ppend ix  1, 
page 70.
3.2 B iochem istry  Results
3.2.1 C yto tox ic ity  Assays
Clonogenic su rv iva l assays, designed to test generational su rv iva l 
were perform ed on fo u r breast cancer cell lines w ith  five drugs. D ata  was 
collected and dose response curves were generated fo r c isp la tin , R f l-  
P tCb and DM -PtO b in  cell lines DC4, DB46, M D A-M B-435, and MDA- 
M B-231. Clonogenic su rv iva l assays were also done us ing  R fl-R e(0 0 ) 3 0 1  
and DM-Re(0 O ) 3 0 1  on D 04  and D B46 cell lines.
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V arious  concentra tions o f drugs were used to determ ine a dose 
response curve. In  DC4 eell lines, c isp la tin , R fl-P tC b  and D M -P tC b 
were used in  the fin a l concentra tions Ix lO  ^M, 1x10-4 SM, ix lQ -SM , Ix lQ - 
5-5M, Ix lQ -^M , and Ix lO  ^M. R fl-Re(CO )3 Cl was used in  the 
concentra tion  1x10-4 ix lO -^M , IxlO-^-^M, Ix lO -^M , and Ix lO ^ M . 
DM-Re(CO)3 Cl was used in  the concentra tions of Ix lO -^M , and 1x10-5 ^M, 
lx lO -6M , and Ix lO ^ M . R fl-Re(CO )3 Cl and DM-Re(CO)3 Cl had lit t le  to no 
effect on DC4 cell lines (see Figure 7, page 40). A t the h ighest 
coneentra tion  o f R fl-R e(C O )3 Cl (Ix l0 -4M ) there was 93% surv iva l, w h ile  
a t the h ighest concen tra tion  o f DM-Re(CO)3 Cl (Ix l0 -4M ) there was 88% 
surv iva l ra te  (see F igure 7, page 40). C isp la tin , R fl-P tC b  and D M -P tC b 
showed c lear dose responses: as concentra tions o f the drugs increased, 
clonogenic su rv iva l decreased (see Figure 7, page 40).
In  D B46 cell lines, c isp la tin , R fl-P tC b  and DM -P tC b were used in  
the fo llow ing  concentra tions 1x10 4M, 1x10 4 SM, Ix lO '^M , 1x10-5 ^M,
1x10 5M, and Ix lO ^ M . R fl-R e(C O )3 Cl was used in  the concentra tions 
1x10-4 5M, 1x10-5M, 1x10-5 5m, 1x10-5M, and Ix lO -^M . DM-Re(CO)3 Cl 
was used in  the concen tra tions Ix l0 -5 M , 1x10-5 5M, ix lO -^M , and 1x10- 
m .  S im ila r to the DC4 ce ll line , R fl-Re(CO )3 Cl and DM-Re(CO)3 Cl 
showed lit t le  effect on D B 46 cells (see Figure 8, page 41). A t the h ighest 
concentra tion  o f R fl-R e(C O )3 Cl (1x10'4-5M) surv iva l was above the eontro l 
value a t 122%, w h ile  a t the  h ighest concentra tion  o f DM-Re(CO)3 Cl 
(lx lO -5M ) eell su rv iva l was 116% (see Figure 8). D B46 cells responded in
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a  d o s e  d e p e n d e n t  m a n n e r  to  c is p la t in ,  R f l - P t C b  a n d  D M - P tC b  (see 
Figure 8).
In  the M D A-M B-435 cell lines, c isp la tin  was used in  the fo llow ing 
coneentra tions 1x10 ^M , Ix lO  ^M, 1x10-4 SM, Ix lO '^M , 1x10 5 SM, 1x10 
6M, Ix lO -^M , and Ix lO -^M . R fl-P tC b  was used in  the eoncentra tions 
lx lO -4M , 1x10-4 5M, Ix l0 -5 M , 1x10-5 5M, Ix lO '^M , Ix lO '^M , and Ix lO -^M . 
DM -P tC b was used in  the concen tra tion  Ix l0 -4 M , 1x10-4 SM, ix lO  5M, 
lxlO-5-5]VI, Ix lO -^M , Ix lO -^M , 1x10 5M, and Ix lO -^M . The M D A-M B-435 
cell line responded in  a dose dependent m anner to  c isp la tin , R fl-P tC b  
and DM -P tC b (see Figure 9, page 42). D M -P tC b and R fl-P tC b  were 
m uch  more effective tha n  c isp la tin  a t in h ib it in g  cell p ro life ra tion  a t the 
h ighest eoncentra tions. A t the h ighest concen tra tion  o f R fl-P tC b  (1x10- 
4M) there was 0.23%  surv iva l in  M D A -M B -435 cells, w h ile  a t the h ighest 
concentra tion  o f D M -P tC b (1x10 4M) there was 0.15%  cell surv iva l. A t 
the same eoncentra tion o f c isp la tin  (1x10 4M) cells treated w ith  c isp la tin  
had a 70% surv iva l rate (refer to F igure 9).
In  the M DA-M B-231 cell line , c isp la tin  was used in  the fo llow ing 
concentra tions Ix lO -^M , Ix l0 -4 M , 1x10 4 SM, Ix l0 -5 M , and Ix lO -^M .
R fl -P tC b and D M -P tC b were used in  the  coneentra tions Ix l0 -4 M , 1x10 
4 5M, 1x10 5M, 1x 10-5 5m , 1x10 5M, and Ix lO ^ M . The M DA-M B-231 cell 
line  responded in  a dose dependent m anne r to c isp la tin , R fl-P tC b , and 
D M -P tC b (see Figure 10, page 43). S im ila r to M D A-M B-435 cells, MDA- 
M B-231 cells were m ost sensitive to R fl-P tC b  and DM -PtCb. Cells
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treated w ith  R fl-P tC b  and DM -P tC b had a lower th a n  1% surv iva l a t a 
ten  fo ld  low er dose (1x10 ^M) th a n  cells treated w ith  c isp la tin  ( Ix lO  ^M) 
(see F igure 10).
D ata  collected fro m  the clonogenic surv iva l assays were used to 
determ ine ECso values, shown in  Table 1 (page 39). Tukey-K ram er HSD 
tests and S tu d e n t’s t-tes ts  were the s ta tis tiea l analysis perform ed to 
show s ign ifica n t differences am ong the ECso values. For a ll s ta tis tica l 
analysis see A ppend ix  II (page 84).
A  Tukey-K ram er tes t com paring the ECso values o f c isp la tin , R f l-  
P tCb, and D M -P tC b in  DC4, DB46, M D A-M B-435 and M DA-M B-231 
showed s ta tis tica lly  s ig n ifica n t differences between c isp la tin  and R f l - 
P tCb, and c isp la tin  and D M -P tC b, in  a ll cell lines except fo r DB46. Th is 
Tukey-K ram er tes t showed no s ign ifican t differences between R fl-P tC b  
and D M -P tC b in  a ll fo u r cell lines. A com parison o f ce ll lines treated 
w ith  c isp la tin  showed no s ign ifican t differences between the ECso in  DC4 
and D B46 cell lines, b u t there were s ign ifica n t differences between 
D C 4 /D B 4 6  and M D A-M B-435, and D C 4 /D B 4 6  and M D A-M B-231. A  
model o f the  ECso values o f R f l -P tCb in  each cell line  showed no 
s ign ifica n t differences between ECso in  the  eell lines. There was a s im ila r 
trend am ong ECso o f D M -P tC b in  each cell line.
More specifically, s ta tis tica lly  s ign ifican t differences were found  in  
S tuden t’s t- te s t and Tukey-K ram er test com paring  the ECso 
concentra tions o f c isp la tin , R fl-P tC b  and D M -P tC b fo r each cell line. In
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the DC4 cell line , s ign ifica n t differences ex is t between ECso values o f 
c isp la tin  and R fl-P tC b . In  the M D A-M B-435 cell line . S tud en t’s t- te s t 
and Tukey-K ram er tes t show s ign ifican t differences between c isp la tin  
and R fl-P tC b , and c isp la tin  and D M -P tC b. In  the M D A-M B-231 cell 
line, there are s ta tis tica lly  s ign ifica n t differences between the ECso 
concentra tions o f c isp la tin  and R fl-P tC b , and c isp la tin  and D M -PtC b. 
There are no s ta tis tica lly  s ig n ifica n t differences between ECso values o f 
c isp la tin , R fl-P tC b  and D M -P tC b in  the DB46 cell line.
S ta tis tica l ana lys is o f a ll cell lines com pared w hen treated w ith  
each d rug  in d iv id u a lly  showed s ign ifica n t differences between cell lines 
when they are treated w ith  c isp la tin . Tukey-K ram er and S tud en t’s t- te s t 
com paring cell lines treated w ith  c isp la tin  showed s ign ifica n t differences 
between DC4 and M D A-M B-435, DC4 and M D A-M B-231, DB46 and 
M D A-M B-231, D B46 and M D A-M B-435, and M DA-M B-231 and MDA- 
M B-435. There were no s ign ifica n t differences between the ECso o f 
c isp la tin  o f DC4 and DB46.
Tukey-K ram er and S tud e n t’s t-te s t showed no s ign ifican t 
differences between the ECso values o f the cell lines w hen treated w ith  
R fl-P tC b  ECso concentra tions. Tukey-K ram er and S tud en t’s t- te s t 
showed no s ign ifican t differences between the ECso determ ined fo r each 
cell lines w hen treated w ith  D M -P tC b.
3.2.2 Flow C y tom etiy  Assays
3.2.2.1 P rop id ium  Iodide S ta in ing
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A synchronous cells were grown, treated w ith  d rug  fo r 1 h o u r o r 24 
hours , s ta ined w ith  PI and analyzed by flow  cytom etry. These da ta  were 
inconclusive , and no t reproducib le . Parental cell lines, M D A -M B -435 
and M D A -M B -231, were synchronized us ing  aph id ico lin , w h ich  b locks in  
the G l /S  phase o f the cell cyele. Once synchronized, the ap h id ico lin  was 
removed and eells were treated w ith  the ECso of c isp la tin , R fl-P tC b , and 
D M -P tC b. Cells were analyzed a t 12, 24 and 48 hours  a fte r tre a tm e n t on 
the  flow  cytom eter.
These da ta  from  synchronized cells showed b lock ing  o f the  cell 
cycle a t 12 ho urs  in  cells treated w ith  R fl-P tC b  and D M -P tC b b u t no t 
c isp la tin . M D A-M B-435 cells treated w ith  c isp la tin  had a cell cycle 
d is tr ib u tio n  s im ila r to the con tro l; the m a jo rity  o f cells were in  Ga, w ith  
over 60% o f the cells being in  th is  phase (see Figure 11, page 44). MDA- 
M B-435 cells treated w ith  the ECso o f R fl-P tC b  were b locked in  G i and 
Ga. 11% o f cells were in  S phase, 48% were in  G i and 40% were in  Ga. 
M D A -M B -435 cells treated w ith  the  ECso o f D M -P tC b were b locked in  S 
phase o f the  cell cycle (70%).
M D A -M B -2 31 cells treated w ith  the ECso of c isp la tin  were s im ila r 
to  the con tro l cells, w ith  a b lock a t Ga a fte r 12 hours (see F igure 12, page 
45). M D A-M B-231 cells treated w ith  ECso o f R f l-PtCb were apoptotie 
and blocked in  G i/S  phases o f the cell cycle. Fifteen percent o f the  cells 
were apoptotie, 38% were in  G i and 38% were in  S phase o f the cell
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cycle. M D A-M B-231 cells treated w ith  D M -P tC b were m ostly  b locked in  
G i and some were he ld  in  S phase 45% and 32%, respectively.
Asynchronous cells, M D A -M B -435 and M D A -M B -231, were treated 
w ith  vary ing  eoncentra tions e isp la tin , R fl-P tC b  and DM -P tC b to 
determ ine d rug  dose effects on in d u c tio n  o f apoptosis. M D A-M B-435 
cells were treated w ith  Ix lO  ^M, Ix lO  ^M, 1x10 ^M, and 1x10 ^M e isp la tin  
and analyzed a fte r 24 ho u rs  us in g  PI s ta in ing. D ata  was analyzed w ith  
M odF it program , w h ieh  takes G i, Ga and S values to be 100% and 
apoptotie  peaks are in  ad d ition  to  the to ta l. There were no differences 
between the cells treated w ith  va ry ing  concentra tions o f c isp la tin  (see 
Table 2, page 46). M D A -M B -435 cells were treated w ith  Ix lO  ^M, 1x10 
5M, 1x10 5M, and 1x10 "^M R fl-P tC b . The h ighest coneentra tion had 
10% o f cells undergo ing apoptosis, and 13% cells treated w ith  Ix lO '^M  
R fl-P tC b  were undergoing apoptosis (see Table 2). Th is trend  is 
reproducib le . M D A-M B-435 cells were treated w ith  Ix lO  ^M, Ix lO  ^M, 
Ix lO '^M , and 1x1 O^M D M -P tC b. S ixteen percent o f cells treated w ith  
Ix lO '^M  D M -P tC b were undergo ing apoptosis. Apoptotie  cells in  
tre a tm en t groups treated w ith  d rugs below th is  concentra tion  were a ll 
less th a n  4% o f the  popu la tion , w h ieh  is  w h a t is  seen in  non-treated eells 
(see Table 2).
M D A -M B -231 eells were treated w ith  the same eoneentrations o f 
drugs as M D A-M B-435 eells. Cells trea ted w ith  vary ing  eoneentrations o f 
c isp la tin  were a ll s im ila r; there were no differenees between trea tm ents
34
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(see Table 3, page 47). Cells treated w ith  R fl-P tC b  were 8% apoptotie a t 
Ix lO '^M  R fl-P tC b  and 15% apoptotie a t the low er concen tra tion  Ix lO ^ M  
(see Table 3). F ifteen pereent o f M D A-M B-231 cells treated w ith  DM- 
PtCb, were undergoing apoptosis a t the  h ighest concentra tion  Ix lO  ^M. 
A ll o the r tre a tm e n t groups were less th a n  3% apoptotie w h ich  is w ha t is 
seen in  non-trea ted  eells (see Table 3).
3.2 .2.2 A nnex in  V  s ta in ing
DC4 cells treated w ith  R fl-P tC b  showed the m ost apoptosis and 
necrosis s ta in ing , a fte r 48 hours  (see Table 4, page 48). In  cells treated 
w ith  R fl-P tC b , 31% were positive fo r apoptosis a fte r 24 ho urs  and 42% 
o f cells treated w ith  R fl-P tC b  were apoptotie  a fte r 48 hours , b u t th is  was 
no t a s ta tis tie a lly  s ign ifica n t difference. W hen treated w ith  R fl-P tC b , the 
num ber o f cells undergo ing neerosis decreased between 24 to 48 hours. 
Cells trea ted w ith  D M -P tC b were undergo ing apoptosis and necrosis 
more th a n  cells treated w ith  c isp la tin , a t 24 hours. A fte r 24 hours, 20% 
and 2.5%  o f cells treated w ith  D M -P tC b were undergo ing apoptosis and 
necrosis, respectively. The num ber o f eells undergoing eell death in  DM- 
PtCb treated cells was n o t s ign ifican tly  d iffe ren t from  the nu m be r o f cells 
undergoing cell death in  c isp la tin  treated eells, a fte r 24 hours.
D B46 cells showed less sens itiv ity  to trea tm en t w ith  d rugs than  
DC4 eells dem onstrated. A fte r 24 hours , 26% o f eells treated w ith  R f l-  
P tCb were undergo ing apoptosis (see Table 5, page 49). A fte r 48 hours 
33% o f cells treated w ith  R fl-P tC b  were undergo ing apoptosis. However,
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these differences were n o t s ta tis tie a lly  s ign ificant. Cells treated w ith  DM - 
PtCb were undergo ing  apoptosis m ore th a n  eells treated w ith  e isp la tin  a t 
24 hours. Th is  tre nd  changed a fte r 48 hours  when 1% more o f the 
c isp la tin  treated p o pu la tion  were undergo ing apoptosis th a n  the DM - 
PtCb treated cells. Th is  tre n d  was n o t s ta tis tica lly  s ign ifican t. A ll 
treated cells were undergo ing more apoptosis than  con tro l cells.
M D A-M B-435 cells showed s im ila r trends to  DC4 and DB46. Cells 
treated w ith  R fl-P tC b  were s ta in ing  positive fo r apoptosis more tha n  
cells treated w ith  D M -P tC b and cells treated w ith  c isp la tin  (see Table 6, 
page 50). O f the cells treated w ith  R fl-P tC b , 28% and 37% o f were 
undergoing apoptosis a fte r 24 and 48 hours, respectively.
M D A -M B -231, the pa ren t line  o f DC4 and DB46, showed more 
sens itiv ity  to c isp la tin  and D M -P tC b treatm ents (see Table 7, page 51).
A t 48 hours , 32% o f cells treated w ith  c isp la tin , 18% o f cells treated w ith  
R fl-P tC b  and 24% o f eells treated w ith  DM -PtCb were undergo ing 
apoptosis. A fte r 24 ho u rs  eells treated w ith  D M -P tC b were undergo ing 
m ore apoptosis, th a n  cells treated w ith  c isp la tin  and R fl-P tC b .
3.2 .3  F luorescent M icroseopy
DC4 cells were treated w ith  the ECso o f c isp la tin , R fl-P tC b  and 
D M -P tC b, sta ined and imaged a fte r 24, 48 and 72 hours . DC4 cells 
treated w ith  R fl-P tC b  were undergo ing apoptosis and necrosis m ore 
th a n  c isp la tin  treated and D M -P tC b treated eells (see F igure 13, page
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52). A fte r 24 hours, 75% o f DC4 cells treated w ith  R fl-P tC b  were 
s ta in ing  positive w ith  Hoechst and 66% were s ta in ing  positive fo r PI (refer 
to Table 8, page 53). A fte r 24 hours , 54% o f DC4 cells treated w ith  DM - 
PtCb were s ta in ing  positive fo r Hoeehst and 40% were positive fo r PI.
The d is tr ib u tio n  o f apoptotie and necro tic  cells re su lting  from  trea tm en t 
w ith  c isp la tin  were s im ila r to the  contro l.
D B46 cells treated w ith  R fl-P tC b  were more apoptotie  and necrotic 
tha n  D M -P tC b treated cells, a t 24 hours  (see Figure 14, page 54). Forty- 
one percent o f cells treated w ith  R fl-P tC b  were s ta in ing  positive fo r early 
apoptosis a fte r 24 hours  and 31% were s ta in ing  positive fo r necrosis, 
a fte r 24 hours. The num be r o f apoptotie  and necrotic cells treated w ith  
R fl-P tC b  decreased a fte r 24 h ou rs  (refer to  Table 9, page 55). Cells 
treated w ith  DM -P tC b were undergo ing cell death in  the greatest 
num bers a t 48 hours. T h ir ty  percent o f cells treated w ith  D M -P tC b were 
s ta in ing  positive fo r Hoechst and 84% o f cells were positive fo r PI, a fter 
48 ho u rs  (see Table 9). Cells treated w ith  c isp la tin  were s im ila r to the 
contro l.
A t a ll tim es m easured, 24, 48 and 72 hours, e isp la tin  treated 
M D A-M B-435 were undergo ing less apoptosis and neerosis tha n  con tro l 
cells, b u t these were no t s ta tis tica lly  s ign ifica n t differences accord ing to 
s tu d e n t’s t-tes ts  (see Figure 15, page 56). Cells treated w ith  D M -P tC b 
were undergo ing  more apoptosis and necrosis th a n  cells treated w ith  
R fl-P tC b  a t 24, 48 and 72 hours. O f cells treated w ith  D M -P tC b 15%,
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15%, and 3% were s ta in ing  positive fo r A nnex in  V  a t 24, 48 and 72 
hours , respective ly (see Table 10, page 57).
M D A-M B-231 cells were more sensitive to R fl-P tC b  th a n  DM - 
PtCb. More R fl-P tC b  treated eells were s ta in ing  positive fo r Hoechst and 
PI, tha n  D M -P tC b treated cells (see Figure 16, page 58). A fte r 48 hours , 
28% o f R fl-P tC b  treated eells were undergo ing early apoptosis. Cells 
treated w ith  c isp la tin  were undergoing more apoptosis and necrosis tha n  
con tro l cells (see Table 11, page 59).
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C isp la tin  (pM) R fl-P tC h  (pM) DM-PtCla (pM)
DC4 5.01+0.33 1.58+0.01* 3.10+0.35
DB46 4.29+1.33 3.90±2.63 2.26+1.09
M D A-M B-435 131.99±2.36 2.1611.63* 4.5211.08*
M DA-M B-231 237.13+0 1.91+0.08* 5.1412.76*
* s ign ifican tly  d i ïe ren t from  c isp la tin , w ith in  cell line  (p<0.05)
Table 1 EC 5 0  Values (|uM)
EC 5 0  values o f DC4, DB46, M D A-M B-435 and M DA-M B-231 
calcu la ted from  clonogenic su rv iva l assays.
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Figure 7 DC4 Dose Response Curve
Log V. Log graph o f da ta  collected from  clonogenic su rv iva l assays o f 
vary ing  concen tra tion  o f C isp la tin , R fl-P tC b , D M -P tC b, R fl-Re(CO )3 Cl 
and DM-Re(CO)3 Cl on DC4 cells. C isp la tin , R fl-P tC b , D M -P tC b da ta  are 
average o f three clonogenic surv iva ls each done in  trip lica te . R f l-  
Re(CO)3 Cl and DM-Re(CO)3 Cl are from  a single experim ent. A ll averaged 
experim enta l da ta  po in ts  have e rro r bars (standard deviation), b u t some 
are sm a lle r th a n  the  sym bol used.
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Figure 8 D B46 Dose Response Curve
Log V. Log graph o f da ta  colleeted from  elonogenie su rv iva l assays of 
va iy in g  concentra tion  o f C isp la tin , R fl-P tC lg , DM -PtCb, R fl-Re(CO )3 Cl 
and DM-Rc(CO)3C1 on D B46 cells. C isp la tin  da ta  are the average o f two 
elonogenie su rv iva l assays each done in  trip lica te . R fl-P tC b , DM -P tC b 
data are average o f three clonogenic su rv iva ls  each done in  trip lica te . 
R fl-Re(CO )3 Cl and DM-Re(CO)3 Cl are from  a single experim ent. A ll 
averaged experim enta l da ta  po in ts  have e rro r bars (standard deviation), 
b u t some are sm alle r th a n  the sym bol used.
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Figure 9 M D A -M B -435 Dose Response Curve
Log V.  Log graph o f da ta  collected from  clonogenic su rv iva l assays o f 
va iy in g  concen tra tion  o f C isp la tin , R fl-P tC b , and D M -P tC b on MDA-M B- 
435 cells. C isp la tin  da ta  are the average o f fo u r clonogenic su rv iva l 
assays each done in  tr ip lica te  or more. R fl-P tC h , D M -P tC b da ta  are 
averages o f three clonogenic surv iva ls  each done in  tr ip lica te . A ll 
averaged experim enta l da ta  po in ts  have e rro r bars (standard deviation), 
b u t some are sm a lle r than  sym bols used.
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Figure 10 M DA-M B-231 Dose Response Curve
Log V. Log graph o f da ta  collected from  clonogenic su rv iva l assays of 
vary ing  concentra tion  o f C isp la tin , R fl-P tC lg , and D M -P tC L on M DA-MB- 
231 cells. C isp la tin  da ta  are the average o f tw o clonogenic surv iva l 
assays each done in  tr ip lica te . R fl-P tC h , D M -P tC b da ta  are the average 
o f three clonogenic su rv iva ls  each done in  trip lica te . A ll averaged 
experim enta l da ta  po in ts  have e rro r bars (standard deviation), b u t some 
are sm alle r th a n  sym bols used.
43
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
C ontro l C isp la tin
C on tro l
No
A ph id ico lin
R f l - P t C b , D M -P tC Ia
Figure 11 M D A-M B-435 Synchronized Cell Cycle F low  C ytom etiy  
M D A-M B-435 cells synchronized w ith  aph id ieo lin  and p ro p id iu m  iodide 
s ta in ing  viewed w ith  flow  cy tom e tiy  a t 12 hours  a fte r tre a tm e n t w ith  
ECso o f c isp la tin , R fl-P tC b , and D M -PtC b. Representative da ta  o f two 
experim ents.
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Figure 12 M D A-M B-231 Synchronized Cell Cycle Flow C ytom etry 
M DA-M B-231 cells synchron ized w ith  aph id ico lin  and p ro p id iu m  iodide 
s ta in ing  viewed w ith  flow  cy to m e tiy  a t 12 hours a fte r trea tm en t w ith  
ECso o f c isp la tin , R fl-P tC b , and D M -PtC b. Representative da ta  o f two 
experim ents.
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C isp la tin  (pM) Apopto tic  (%) G i (%) 8 (% ) Ga(%)
0 2.7 37.38 46.08 16.54
1 2.75 34.16 48.72 17.12
10 3.78 35.77 46.55 17.67
100 2.79 37.96 44.87 17.16
1000 1.27 36.22 41.99 21.79
R fl-P tC b  (pM) A popto tic  (%) G i (%) S(% ) Gz(%)
0 2.7 37.38 46.08 16.54
0.1 1.46 37.74 44.38 17.88
1 3.11 36.1 45.83 18.07
10 13.61 33.77 49.38 16.85
100 10.33 38.8 45.93 15.26
D M -P tC b (pM) Apopto tic  (%) G i (%) Ga (%)
0 2.7 37.38 46.08 16.54
0.1 3.23 37.24 45.28 17.48
1 1.84 36.16 47.01 16.83
10 2.57 47.15 25.09 27.75
100 16.18 42.47 42.11 15.43
Table 2 PI S ta in ing  o f M D A-M B-435 Treatm ents w ith  Vary ing 
C oncentra tions o f D rugs a t 24 hours
Increasing concentra tions o f c isp la tin , R fl-P tC b , and DM-PtCb. 
P rop id ium  Iodide s ta in ing  was used to determ ine b locks in  cell cycle and 
analys is was done w ith  flow  cytom etiy . D ata  represent percentage of 
cells in  phases o f the cell cycle.
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C isp la tin  (pM) A pop to tic  (%) G i (%) S(% ) G2(%)
0 1.57 37 46.74 16.25
1 1.03 41.21 43.17 15.62
10 2.31 39.92 45.03 15.05
100 1.95 41.41 42.04 16.55
1000 2.16 51.28 36.74 11.98
R fl-P tC b  (pM) A pop to tic  (%) G i (%) S(% ) G2(%)
0 1.57 37 46.74 16.25
0.1 0.64 38.73 45.45 15.82
1 0.24 38.4 47.32 14.28
10 14.98 41.03 43.11 15.86
100 8.24 41.74 47.35 10.91
D M -P tC b (pM) A pop to tic  (%) G i(% ) S(% ) G2 (%)
0 1.57 37 46.74 16.25
0.1 0.47 40.81 44.21 14.98
1 0.62 38.9 46.29 14.81
10 2.21 55.23 27.72 17.05
100 14.73 36.76 49.62 13.62
Table 3 PI S ta in ing  o f M D A-M B-231 Treatm ents w ith  V ary ing  
C oncentra tions o f D rugs a t 24 hours
Increasing concentra tions o f c isp la tin , R fl-P tC b , and D M -PtC b. 
P rop id ium  Iodide s ta in ing  was used to determ ine b locks in  cell cycle. 
Data represent percentage o f cells in  phases o f the cell cycle.
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Treatm ent Apopto tic  (%) Necrotic (%)
24h  con tro l 16.90±3.04 2.34+1.82
24 h o u r c isp la tin 16.47+1.78 3.47+1.88
24 h o u r R fl-P tC b 30.91+10.36 3.94+4.80
24 h o u r D M -P tC b 20.36±7.07 2.49+0.55
48 h o u r con tro l 22.27±6.09 2.65+1.60
48 h o u r c isp la tin 24.90+14.27 2.45+1.73
48 h o u r R fl-P tC b 41.8+4.46 1.46+0.84
48 h o u r D M -P tC b 21.31+12.43 3.21+1.80
Table 4 A nnexin  V  S ta in ing  o f DC4 Cells
A nnex in  V s ta in ing  analyzed by the flow  cytom eter. DC4 cells treated 
w ith  ECso o f c isp la tin , R fl-P tC b  and D M -P tC b analyzed a fte r 24 and 48 
hours. Average o f tr ip lica te  experim ents.
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Treatm ent A pop to tic  (%) Necrotic (%)
24h con tro l 19.19+1.96 1.36+0.64
24 h o u r c isp la tin 19.68+5.06 2.99+2.75
24 h o u r R fl-P tC b 26.76+6.91 3.68+3.10
24 h o u r D M -P tC b 22.03+3.01 1.63+0.50
48 h o u r co n tro l 24.13+1.95 1.49+0.72
48 h o u r c isp la tin 27.07+4.82 1.24+0.89
48 h o u r R fl-P tC b 33.05+4.00 1.31+0.69
48 h o u r D M -P tC b 26.75+4.37 1.30+0.88
Table 5 A nnex in  V  S ta in ing  o f D B46 Cells
A nnex in  V  s ta in in g  analyzed by the flow  cytom eter. D B46 cells treated 
w ith  ECso o f e isp la tin , R fl-P tC b  and D M -P tC b analyzed a fte r 24 and 48 
hours. Average o f tr ip lica te  experim ents.
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Trea tm ent A pop to tic  (%) Necrotic (%)
24h con tro l 19.85+12.00 2.41+0.52
24 h o u r c isp la tin 16.45+10.48 1.37+0.21
24 h o u r R fl-P tC b 28.22+24.80 2.42+0.74
24 h o u r D M -P tC b 22.64+15.78 1.30+0.23
48 h o u r con tro l 20.52+2.46 0.91+0.47
48 h o u r c isp la tin 18.46+3.13 1.65+1.09
48 h o u r R fl-P tC b 36.54+23.81 1.49+0.73
48 h o u r D M -P tC b 24.17+9.17 1.60+0.17
Table 6 A nnex in  V  S ta in ing  o f M D A -M B -435 Cells
A nnex in  V  s ta in ing  analyzed by the flow  cytom eter. M D A-M B-435 cells 
treated w ith  ECso o f c isp la tin , R fl-P tC b  and D M -P tC b analyzed a fte r 24 
and 48 hours. Average o f dup lica te  experim ents.
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Treatm ent A popto tic  (%) Necrotic (%)
24h co n tro l 16.48+8.65 1.56+0.23
24 h o u r c is p la tin 18.40+13.69 3.25+2.64
24 h o u r R fl-P tC b 20.99+15.20 3.60+2.49
24 h o u r D M -P tC b 22.88+13.97 2.74+1.64
48 h o u r con tro l 15.89+0.24 1.71+0.27
48 h o u r c is p la tin 31.88+22.80 2.19+0.27
48 h o u r R fl-P tC b 17.97+1.63 1.96+0.68
48 h o u r D M -P tC b 24.02+5.01 2.28+1.02
Table 7 A nnex in  V  S ta in ing  o f M DA-M B-231 Cells
A nnexin  V  s ta in in g  analyzed by the flow  cytom eter. M D A -M B -2 31 cells 
treated w ith  ECso o f e isp la tin , R fl-P tC b  and D M -P tC b analyzed a fte r 24 
and 48 hours . Average o f dup lica te  experim ents.
51
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
: INM
Figure 13 DC4 M icroscope Images 24 hours  fo llow ing trea tm en t 
Cells were treated w ith  ECso value o f each drug. F luorescent m icroscope 
images o f DC4 cells sta ined w ith  no th ing , Hoechst and PI sta ins. C on tro l 
(A-C), c isp la tin  (D-F), R fl-P tC b  (G-1), D M -P tC b (J-L), b r ig h t fie ld  (A, D, G, 
J), Hoechst (B, E, H, K) and PI (C, F, 1, L) a t 24 hours. For Hoechst and 
PI sta in , on ly b r ig h tly  g low ing cells were counted as positive. A rrow s 
ind ica te  examples o f positive cells.
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% Apoptotic
12 hour 24 hour 4 8  hour 72 hour
Control 7 .1 7 + 3 .4 6 4 .7 3 + 0 .9 9 1.75+0.84 1 .17+1.08
Cisplatin 5 .4 2 ± 2 .0 9 7 .1 8 ± 1 .9 0 4.8+0 1.35+ 0 .60
R fl-
PtCb 7 2 .3 + 5 .2 0 7 4 .6 + 2 2 .0 5 4 .5 + 9 .0 0 3 8 .8 + 2 0 .8
DM-
PtCla 1 .28+2.22 5 4 .3 + 2 4 .0 13.6±3.0 6 .4 8 ± 4 .1 7
12 hour
% Necrotic
24  hour 4 8  hour 72 hour
Control 3 .4 7 + 3 .0 8 1 .36+ 0 .77 0+0 1.12+ 1 .06
Cisplatin 1 .19+ 2 .06 2 .2 0 ± 0 .9 4 0.8+0 0 .8 9 ± 0 .8 0
R fl-
PtCb 7 6 .7 5 + 3 .3 3 6 6 .4 + 1 7 .2 4 4 .2 + 2 0 .8 3 3 .5 ± 1 7 .8
DM-
PtCb 0±0 3 9 .1 ± 2 0 .8 7 .6 5 ± 2 .9 2 3 .62+ 2 .79
Table 8 DC4 F luorescent M icroscopy D ata
Apoptosis and Necrosis as determ ined w ith  Hoechst s ta in ing  and PI 
s ta in ing , respectively. C om pute r images were m an ua lly  counted for 
B rig h t F ie ld , Hoechst and PI positive cells. ECso concentra tions were 
used fo r each o f the  drugs. These da ta  are represent averages o f 
experim ent done in  trip lica te .
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Figure 14 D B46 M icroscope Images 24 hou rs  fo llow ing trea tm en t 
Cells were treated w ith  ECso value o f each drug. F luorescent m icroscope 
images o f DC4 cells sta ined w ith  no th ing , Hoechst and PI stains. C on tro l 
(A-C), c isp la tin  (D-F), R fl-P tC b  (G-1), D M -P tC b (J-L), b r ig h t fie ld  (A, D, G, 
J), Hoechst (B, E, H, K) and PI (C, F, 1, L) a t 24 hours. For Hoechst and PI 
s ta in , on ly  b r ig h tly  g low ing cells were counted as positive. A rrows 
ind ica te  examples o f positive cells.
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% Apoptotic
2 4  hour 4 8  hour 72 hour
Control 1 .75+ 2 .08 1 .11+1.92 1 .99+ 0 .64
Cisplatin 1 .64+ 0 .63 1.27+0 2 .45+ 0 .89
R fl-
PtCla 4 4 .3 + 2 0 .4 3 6 .8 + 2 9 .7 8 .6 5 + 6 .6 4
DM-
PtCla 19 .3+ 8 .40 29 .4+ 12 .1 15.3+21.5
% Necrotic
2 4  hour 4 8  hour 72 hour
Control 0 .9 0 + 1 .5 6 1.11+1.9 0 .8 7 + 0 .2 7
Cisplatin 1 .00+ 0 .23 0 .64+0 1.35+ 1 .28
R fl-
PtCla 3 1 .6 + 2 0 .3 2 8 .6 + 1 8 .6 7 .97+ 7 .41
DM-
PtCla 8 .0 8 + 3 .6 6 8 4 .3 + 2 .3 6 11.2+17.3
Table 9 D B46 F luorescent M icroscopy D ata
Apoptosis and Necrosis as determ ined w ith  Hoechst s ta in ing  and PI 
s ta in ing , respectively. C om puter images were m a n ua lly  counted fo r 
B rig h t Fie ld, Hoechst and PI positive cells. ECso concentra tions were 
used fo r each o f the drugs. These da ta  represent average o f experim ent 
done in  trip lica te .
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Figure 15 M D A -M B -435 M icroscope Images 24 hours  fo llow ing  tre a tm en t 
Cells were treated w ith  ECso value o f each drug. F luorescent m icroscope 
images o f DC4 cells sta ined w ith  no th ing , Hoechst and PI sta ins. C on tro l 
(A-C), c isp la tin  (D-F), R fl-P tC h  (G-I), D M -P tC b (J-L), b r ig h t fie ld  (A, D, G, 
J), Hoechst (B, E, H, K) and PI (C, F, 1, L) a t 24 hours. For Hoechst and PI 
s ta in , on ly  b r ig h tly  g low ing cells were counted as positive. A rrow s 
ind ica te  examples o f positive  cells.
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% Apoptotic
2 4  hour 48  hour 72  hour
Control 2 .8 9 + 0 .7 8 2 .8 9 + 3 .4 0 1 .68+ 0 .65
Cisplatin 1 .22+0.69 1.22+0.31 1 .66+ 0 .25
R fl-
PtCb 7 .7 2 + 1 .2 5 7 .7 2 + 4 .5 4 3 .0 1 + 2 .3 6
DM-
PtCb 15.4+0.36 15.4+13.3 3 .8 1 + 3 .3 8
% Necrotic
2 4  hour 48  hour 72  hour
Control 0 .8 2 + 0 .3 4 0 .7 3 + 0 .6 3 1 .48+ 0 .28
Cisplatin 0 .66+ 0 .21 0 .5 3 + 0 .6 2 1 .66+ 0 .25
R fl-
PtCb 1.87+0.45 1 .11+0.23 2 .4 5 + 2 .1 6
DM
PtCla 4 .85+ 3 .81 6 .1 7 + 8 .1 3 2 .5 5 + 2 .0 2
Table 10 M D A-M B-435 F luoreseent M icroscopy 
Apoptosis and Necrosis as determ ined w ith  Hoechst s ta in ing  and PI 
s ta in ing, respectively. C om pute r images were m anua lly  counted fo r 
B rig h t Field, Hoechst and PI positive cells. ECso coneentra tions were 
used fo r each o f the  drugs. These da ta  are representing average of 
experim ent done in  trip lica te .
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Figure 16 M D A-M B-231 M icroscope Images 24 hou rs  fo llow ing trea tm e n t 
Cells were treated w ith  ECso value o f each drug. F luorescent m icroscope 
images o f DC4 cells sta ined w ith  no th ing , Hoechst and PI sta ins. C ontro l 
(A-C), c isp la tin  (D-F), R fl-P tC b  (G-1), D M -P tC b (J-L), b r ig h t fie ld  (A, D, G, 
J), Hoechst (B, E, H, K) and PI (C, F, 1, L) a t 24 hours. For Hoechst and PI 
s ta in , on ly  b r ig h tly  g low ing cells were counted as positive. A rrow s 
ind ica te  examples o f positive cells.
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% Apoptotic
2 4  hour 4 8  hour 72 hour
Control 1 .32+ 0 .68 1 .53+1.42 0 .8 2 + 0 .7 5
Cisplatin 4 .3 7 + 2 .4 0 8 .7 7 + 1 0 .4 3 .2 6 + 0 .9 4
R fl-
PtCb 15.7+7.21 27 .1 + 1 9 .9 9 .15 + 6 .8 1
DM-
PtCb 6 .5 5 + 1 .1 8 16.2+14.9 3 .0 6 + 0 .8 2
% Necrotic
2 4  hour 48  hour 72 hour
Control 0 .97 + 0 .0 9 0 .3 1 + 0 .2 8 0+0
Cisplatin 2 .45 + 1 .5 2 3 .4 9 + 4 .0 9 2 .1 3 + 0 .5 0
R fl-
PtCla 17.2+ 6 .37 10 .4+ 5 .96 3 .0 0 + 2 .2 4
DM-
PtCla 4 .8 7 + 2 .2 7 8 .2 5 + 1 .4 5 1.60+ 0 .75
Table 11 M DA-M B-231 F luorescent M icroscopy Data 
Apoptosis and Necrosis as de term ined w ith  Hoechst s ta in ing  and PI 
s ta in ing, respectively. C om pute r images were m anua lly  counted for 
B rig h t Field, Hoechst and PI positive cells. ECso concentra tions were 
used fo r each o f the drugs. These da ta  are representing average of 
experim ent done in  trip lica te .
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CHAPTER 4
DISCUSSION
4.1 O rganic Synthesis D iscussion
F our organom eta llic  com pounds, two p la tinum (II) and  two 
rhen ium (I) con ta in ing , were synthesized as discussed prev ious ly  (see 
M ateria ls  and M ethods Section). The R fl-P t( ll)  com plex was synthesized 
us in g  1,5-cyclooctadiene p la tin u m  d ich lo ride  (COD-PtCb) to afford  be tter 
y ie lds and sho rte r tim efram es fo r synthesis [25]. Use o f CO D-PtCb 
allowed fo r h igher y ie lds because bo th  reactants were soluble in  organic 
solvents. Previous a ttem p ts  a t p la tin u m  coord ina tion  were done us in g  
KaPtCh in  an ac id ic  aqueous layer and the ligand in  an organic layer. 
Once synthesized, a ll fo u r m eta l complexes are stable ye llow  solids, 
so luble in  DMSG (used fo r b iochem ica l studies). The s tru c tu re  o f a ll 
com pounds were con firm ed us ing  ^H and i^C NMR.
R fl-P tC b  and R fl-R e(C Ü 3 )Cl were synthesized from  the 
uncoord ina ted  R f l ligand. The ligand was synthesized as p rev ious ly  
described and characterized w ith  iR , and ^^F NMR, and elem ental 
analysis. ^H and NMR gave expected chem ical sh ifts  fo r the ligand. 
The s tru c tu re  was confirm ed by e lem ental analysis; C, H and N atom ic 
ra tios  were w ith in  0.28%  o f the theore tica l values.
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The novel com pounds R fl-P tC b  and R fl-R e(C 0 3 )Cl were analyzed 
by NMR and e lem ental analysis, nm R  was used to con firm  the 
a ttachm ent o f the 4 ,4 ’-b is (4 ,4 ,4 -tr iflu o ro bu ty l) ta ils . The fluo rine  sh ifts  
a t -71 and -66 ppm  are tr ip le ts  and are s p lit by  th e ir  ne ighboring 
hydrogens. S im ila r sh ifts  have been determ ined by G arelli fo r the 
synthesis o f s im ila r flu o rine  ta il con ta in in g  b ip y rid y l com pounds [19].
R fl-P tC b  and NMR show sh ifts  th a t can be appropria te ly  
iden tified  us ing  spectra o f the pa ren t ligand. The notable differences are 
the arom atic  sh ifts  o f the coord inated com plex are deshielded com pared 
to the p a ren t ligand (see append ix  1, page 70). E lem ental analysis 
con firm s the coo rd ina tion  o f the  m eta l center to the ligand and the ligand 
s truc tu re , shown by the ca lcu la ted  ra tios  o f C, H and N atoms, a ll were 
w ith in  0.15%  o f theore tica l values.
R fl-Re(CO )3 Cl NMR spectra have trends s im ila r to the Pt(ll) 
complex, w ith  the arom atic  hydrogens being sh ifted dow nfie ld o f the 
corresponding pa ren t chem ical sh ifts . A ll e lem ental analyses were w ith in  
0.18% o f the theore tica l values.
D M -P tC b and DM-Re(CO)3 C l were analyzed by NMR, as they had 
previously been synthesized by B ie lli and Van W allendael, respectively 
[21 , 22 ].
D M -P tC b was synthesized us in g  adapted procedures from  B ie lli 
[26]. The synthesis was done u n d e r Ng gas, and p u rifica tio n  was done 
w ith  f iltra tio n  and HgO rinses. Proton chem ica l sh ifts  o f D M -P tC b
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correspond to those observed by B ie lli [26]. The chem ica l sh ifts  o f the 
a rom atic  hydrogens are observed dow nfie ld , re la tive to  the  uneom plexed 
ligand, w hen the b ip y rid y l n itrogens are coord inated to  p la tin u m , due to 
the e lectron w ith d raw a l by the m eta l center 6 /6T1 9 .28ppm , 3 /3 ’H 
8 .39ppm , and 5 /541 7.65ppm .
DM-Re(CO)3 C l spectra had chem ical sh ifts  s im ila r to those 
p rev ious ly  found  by V an W allendael [27]. The syn the tic  scheme was 
derived from  Van W allendael, et. al. and adapted w ith  the use o f benzene 
as the solvent, the  re flu x  tim e was shorted from  21 h ou rs  to  4 hours.
The a rom a tic  chem ical sh ifts  o f the m eta l coord inated ligand  were 
dow nfie ld  o f the corresponding sh ifts  in  the uncoord ina ted  ligand, 6 /6 ’H 
8.8ppm , 3 /3 ’H 7 .94ppm  and 5 /5 ’H 7 .31ppm . The NMR o f DM - 
Re(CO)3 Cl showed two sh ifts  a t 200 and 197ppm, corresponding to the 
three carbonyl m oieties attached to the  m eta l center. The fu rth e s t 
dow nfie ld  s h ift corresponds to the tw o carbonyl groups tra ns  to  the 
n itrogens o f the b ip y ridy l. The uphe ld  s h ift corresponds to the carbonyl 
tra n s  to the ch lorine.
Synthesis o f two novel and two prev ious ly  developed m eta l 
complexes was done th roug h  novel syn the tic  routes. C om pounds were 
relatively  h igh  pu rity  (above 99%  aeeord in g  to e lem en ta l an a ly sis), a s  
determ ined by NMR and elem ental analysis. B iochem ical assays were 
done to determ ine i f  these novel d rugs have any po ten tia l an ti-cancer 
properties.
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4.2 B iochem is try  D iscussion
C isp la tin  has been in  use as a chem otherapy agent and DNA 
a lky la tin g  agent fo r 30 years. Its  tox ic side effects l im it  the app lica tions 
fo r c lin ica l trea tm ent. In  ad d ition , tu m o r cells can gain resistance to 
c isp la tin  over the  course o f trea tm ent. These reasons m ake i t  desirable 
to develop new drugs th a t overcome c isp la tin  resistance and to x ic ity  
w hile  tre a tin g  a broader range o f cancers. Since the developm ent o f 
c isp la tin  in  the  1970’s there have been thousands o f p la tin u m  derivatives 
synthesized and tested fo r b io logical effects [10]. C arbop la tin  is  a 
c isp la tin  derivative th a t is  c u rre n tly  in  use as a c lin ica l tre a tm e n t fo r 
ovarian, cervica l, non -sm a ll ce ll lun g  and head and neck cancers. More 
recently, o xa lip la tin  has been FDA approved fo r the trea tm en t o f 
colorectal cancer [10].
I t  was hypothesized th a t the  novel c isp la tin  derivatives synthesized 
in  th is  s tudy  w ou ld  be as effective as and act in  a m echanism  s im ila r to 
c isp la tin .
Previous w o rk  on novel c isp la tin  derivatives has shown, in  m ost 
cases, th a t c isp la tin  has a low er ECso tha n  its  derivatives. In  the hum an  
ovarian cancer cell line A2780, ca rbop la tin  has an ECso 7.66 pM and 
c isp la tin  has an E C so  o f 1.37 pM [40]. These resu lts  are typ ica l o f the 
trend  fo r o the r p rev ious ly  synthesized c isp la tin  derivatives. The 
p la tin u m  com pounds designed in  th is  s tud y  were found  to have lower 
ECso values th a n  c isp la tin  in  a ll cell lines. Since c isp la tin  is  dose-lim ited
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by its  side effects, these novel derivatives have po ten tia l the rapeu tic  uses 
because a lower concentra tion  o f d ru g  is  required to  induce the same 
effects as c isp la tin .
The c ritic a l ta rge t o f c isp la tin  is  assum ed to be DNA. W hen DNA is 
damaged, cell cycle checkpoin ts ensure the a rrest o f the  cell cycle to 
a llow  fo r repa ir o f the DNA damage. A  b lock a t the G i/S  checkpo in t 
prevents synthesis o f damaged DNA and a b lock a t the  G 2 /M  checkpo in t 
a llow s fo r correction  o f DNA damage before m ito tic  events begin. In  
Chinese ham ster ova iy  (CHO) cells, c isp la tin  tre a tm e n t induces a b lock 
in  the Gg phase o f the cell cycle [35]. Mouse leukem ia cells were found  to 
slow down th rou g h  S phase and u ltim a te ly  a rrest in  G2  w ith  c isp la tin  
tre a tm e n t [41]. The h u m an  breast cancer cell line, MCF7, was found  to 
have a tra n s ie n t b lock in  S phase a fte r trea tm en t w ith  c isp la tin  [41].
Cells synchron ized w ith  a p h id ico lin  w ill be blocked a t G i/S  in terphase,
12 hou rs  a fte r the rem oval o f the ap h id ico lin  we found  cells to be in  G2  
phase, as expected. We found  the con tro l cells and the c isp la tin  treated 
synchronized cells were accum u la ting  in  the G2  and S phases o f the  cell 
cycle a fte r 12 hours, (see F igure 11, page 44). In  M D A-M B-435 cells, 
there was an increase o f 7% in  the S phase between the c isp la tin  treated 
and con tro l cells. I t  appears th a t there was no in h ib it io n  o f the cell cycle 
by  c isp la tin , the c isp la tin  treated cells trave l th roug h  the cell cycle a t the 
same ra te  as the con tro l cells.
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C isp la tin -trea ted  cells die by two pathways, apoptosis o r necrosis. 
C isp la tin ’s chem otherapeutic  effect is th o u g h t to be an apopto tic  
pa thw ay induced  by DNA damage [42]. Apoptosis is detected by a 
nu m be r o f cha rac te ris tic  m orpholog ica l changes to the cell, in c lu d in g  
nuc lear condensation, m em brane b lebbing and p roduction  o f apopto tic  
bodies. Cells w ill undergo a nu m b e r o f b iochem ical changes as well, 
such as the caspase cascade, the  release o f cytochrom e c from  the 
m ito chon d ria  and the flip p in g  o f phospha tidy l serine to the ex trace llu la r 
side o f the  ce llu la r m em brane. We were able to detect the flip p in g  of 
phospha tidy l serine w ith  A nnex in  V  sta in . A nnexin  V  s ta in ing  ind ica ted 
th a t a t the  EC50 o f c isp la tin , 16.47% and 24.90%  o f DC4 cells were 
undergoing th is  early apopto tic  event a t 24 and 48 hours, respectively 
(refer to  Table 4, page 48). S im ila r trends are seen in  the o ther cell lines. 
The nu m be r o f apopto tic  events increases between 24 and 48 hours  
fo llow ing tre a tm e n t w ith  c isp la tin .
R fl-Re(CO )3 Cl and DM-Re(CO)3 Cl were found to have lit t le  effect in  
DC4 and D B46 cell lines. I t  appears th a t the cy to tox ic ity  o f these drugs 
requires the p la tinum (II) center. There were no differences between the 
R fl-Re(CO)3 Cl and DM-Re(CO)3 CI clonogenic surv iva l assays as 
com pared to the  con tro l (see figures 7 and 8, pages 37and 38).
Previous w o rk  has been done to determ ine the cy to tox ic ity  o f 
fluo rous su b s titu e n t con ta in in g  b ip y rid y l p la tin u m  com pounds. G arelli, 
et. al. describes the synthesis and cy to tox ic ity  o f fluo rous b ip y ridy ls  in
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liposom es [20]. They found th a t the fluo rou s  p la tin u m  com pounds were 
a ll less e ffic ien t a t ind u c in g  cell death th a n  c isp la tin . The G are lli 
com pounds had long 4 /4 ’ su b s titue n t, w h ich  conferred am ph ipa th ic  
characte r on the ligands. We have u tilize d  a sho rte r 4 /4 ’ sub s titue n t, so 
there is no need to incorporate the com pound in to  a liposom e fo r use. 
U n like  G are lli’s com pounds, R fl-P tC b , o u r novel c isp la tin  derivative, was 
found  to be more effective tha n  c isp la tin  a t in d u c in g  cell death. In  a ll 
cell lines b u t DB46, i t  had the lowest ECso (refer to Table 1, page 39).
Flow cy tom e tiy  o f synchronized cells (treated w ith  aph id ico lin ) 
sta ined w ith  PI ind ica tes th a t a fte r 12 hours  the M D A-M B-435 cells are 
being he ld  u p  in  G i and Gg phases o f the  cell cycle (refer to Figure 11, 
page 44). The M DA-M B-231 cells treated w ith  R fl-P tC b  are m ostly  held 
in  G i and S phases. These cell cycle in h ib it io n s  o f R fl-P tC b  treated cells 
are d iffe ren t th a n  the b lock seen in  c isp la tin  treated cells, in d ica ting  
there m ay be a d iffe ren t m echan ism  o f ce ll death and damage between 
c isp la tin  and R fl-P tC b . T rea tm ent w ith  increasing concentra tions o f 
R fl-P tC b  has a dose dependent effect on apoptosis between 0 .1 -10 pM 
(Tables 2 and 3, pages 43-44). A t the h ighest concentra tion , 100 pM, 
there is less apoptosis (10.33%) th a n  a t 10 pM (13.61%) in  M D A-M B-435 
cells treated w ith  R fl-P tC b . Th is m ay be due to the increase in  necrotic 
cell death a t 100 pM. S im ila r resu lts  were seen in  M DA-M B-231 cells 
treated w ith  R fl-P tC b . The apopto tic  in d u c in g  a b ility  o f R fl-P tC b  is also 
supported by A nnex in  V  s ta in ing. There is  an increase A nnexin  V
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sta in ing, in d ica tin g  there was an increase in  the nu m be r o f apopto tic  
DC4, DB46, M D A -M B -435 and M DA-M B-231 cells between 24 and 48 
hours. In  a ll b u t one case the num be r o f apoptotic cells in  R fl-P tC b  
treated groups exceeds the  num be r o f apoptotic cells in  c isp la tin  treated 
groups.
F luorescent m icroscopy s ta in ing  o f R fl-P tC b  treated cells was 
qu icker and b rig h te r, in d ica tin g  a k ine tic  difference. In  DC4 cells, R f l-  
P tCb tre a tm e n t induced cell death in  77% o f cells a fte r 12 h o u rs  and 
74.6%  o f cells, a fte r 24 hours . The differences between R fl-P tC b  treated 
cells a t 12 and 24 hours  are no t s ign ifican t, b u t m ay ind ica te  a ra p id  
death response from  th is  drug. R fl-P tC b  appears to be in d u c in g  
necrotic cell death in  DC4 cells w ith in  12 hou rs  a fte r trea tm ent. These 
h igh  levels o f necrosis are n o t seen in  R f l -P tCb tre a tm en t in  o the r cell 
lines, b u t the  levels o f necrosis are h igher tha n  the o ther d rugs tested. 
Hoechst and PI s ta in ing  o f cells ind ica ted th a t cell death was induced by 
bo th  apoptosis and necrosis. In  DC4 and DB46 cell lines, the  nu m be r o f 
apoptotic cells treated w ith  R fl-P tC b  declined a fte r 24 hours. Th is  m ay 
be due to the loss o f cells th a t began to die im m edia te ly  a fte r tre a tm e n t 
and d id  no t survive to the 48 and 72 h o u r tim e po in ts . In  D B46 cells, 
there was a large and reproducib le  increase in  necrosis between 24 and 
48 hours  in  cells treated w ith  DM -PtCb. In  M DA-M B-231 cells, the 
num ber o f apopto tic  cells increased from  24 hou rs  (15.7%) to 48 hours
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(27.1%). A ll cell death assays ind ica te  there is  more apoptotic th a n  
necrotic cell death in  cells treated w ith  R fl-P tC b .
F luorescent m icroscopy o f D B46 cells shows c isp la tin  trea tm en t 
having lit t le  effect on apoptosis and necrosis (see Table 9, page 55). I t  is 
possible the cons titu tive  expression o f H sp27 is o ffering some pro tection  
to these cells from  the le th a l dose o f c isp la tin . I t  m ay also be offering 
some early pro tection  aga inst apoptosis and necrosis in  cells treated w ith  
R fl-P tC b  and D M -PtC b: the percent o f apoptotic and necrotic cells a t 24 
hours  in  DB46 cells is less th a n  the percent a t 24 hours  in  DC4 cells. 
D M -P tC b induced necrosis in  D B46 a t an u n u su a lly  h igh  rate a fte r 48 
hou rs  o f trea tm ent, a ra te  n o t seen in  o the r cell lines.
D M -P tC b tre a tm e n t e lic ited  b io logical effects d iffe ren t from  
c isp la tin  effects in  a ll ce ll lines. PI s ta in ing  used w ith  flow  cytom etry 
ind ica tes th a t 70% M D A-M B-435 cells treated w ith  D M -P tC b are being 
blocked a t the S phase o f the cell cycle. Th is is  a d iffe ren t b lock tha n  
seen a fte r 12 hours  in  c isp la tin  and R fl-P tC b  treated cells. Th is 
suggests the m echan ism  o f action  o f D M -P tC b is un ique  from  th a t o f the 
o ther tw o drugs. In  M D A-M B-231 cells, the DM -P tC b treated cells are 
blocked m a in ly  in  G i and S phases, s im ila r to R fl-P tC b  treated cells. PI 
s ta in ing  a fte r tre a tm e n t w ith  increasing concentra tion  o f D M -P tC b 
dem onstrates a dose dependent increase in  apoptosis. There is  no clear 
dose dependent response in  cell cycle in h ib itio n , b u t the  m a jo rity  o f cells 
were found  to be arrested in  G i and S phase. The M D A-M B-231 cells
68
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
treated w ith  D M -P tC b are consis ten t w ith  o the r find ings, except a t 10 pM 
the cells are accum u la ting  in  G i. Th is is s im ila r to M D A-M B-231 cells 
treated w ith  10 pM o f D M -PtC b, w h ich  are also being he ld in  G i. Th is  
suggests there m ay be a dose responsive cell cycle b lock w ith  D M -PtC b.
A nnex in  V  s ta in ing  us ing  the flow  cytom eter ind ica tes the m a jo rity  
o f cells are dy ing  by apoptotic and n o t necrotic m echanism s, in  a ll cell 
lines. In  a ll cases, w ith  the exception o f M DA-M B-231 cells a t 48 hours, 
there is  less apoptosis in  D M -P tC b treated cells th a n  R fl-P tC b  treated 
cells. These da ta  are supported by the m icroscopy images. DC4, DB46 
and M D A-M B-231 cells undergo less apoptosis when treated w ith  DM - 
PtCb th a n  w ith  R fl-P tC b . The num be r o f apoptotic D M -P tC b treated 
DC4 cells decline a fte r 24 hours, s im ila r to  the R fl-P tC b  treated DC4 
cells. D B46 and M DA-M B-231 cells reach a m ax im um  nu m be r o f 
apopto tic  cells a t 48 hours.
The clonogenic surv iva l, flow  cytom etry  and fluorescent m icroscopy 
da ta  suppo rt a conclus ion th a t these three drugs w o rk  th ro u g h  d iffe ren t 
in tra c e llu la r m echanism s, o r have d iffe ren t sites o f damage. These da ta  
ind ica te  th a t m echanism s o f action  m ay be cell line  dependent b u t are 
un ique  from  d rug  to drug. There are a nu m be r o f po ten tia l exp lana tions 
fo r the difference in  tox ic ity  between the drugs.
Decreased d rug  e fflux  is a po ss ib ility . The copper transpo rte r, 
ATP7B, has been shown to remove c isp la tin  from  the in tra c e llu la r space 
[43]. I t  is  possible th is  tra n spo rte r and o ther c isp la tin  tra nspo rte rs  do
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no t move R fl-P tC b  and D M -P tC b o u t o f the cell as e ffic ien tly  as they do 
c isp la tin .
D ifferences in  tox ic ities  between the three drugs m ay arise by th e ir  
d iffe ren t a ffin ities  fo r DNA a n d /o r  p ro te ins. O nly 1% o f cytosolic 
c isp la tin  in te rac ts  w ith  nuc lear DNA, the  o ther 99% in te racts  w ith  
cytoso lic pro te ins, m em brane pro te ins, lip ids , RNA and m itochondria l 
DNA [42]. The 1% th a t in te rac ts  w ith  DNA is assumed to be the cause o f 
c isp la tin  tox ic ity . R fl-P tC b  and D M -P tC b m ay have an increased a ffin ity  
fo r DNA, m ak ing  them  be tte r chem otherapeutic  agents. They m ay also 
b in d  and inactiva te  cytosolic p ro te ins, leading to an in d u c tio n  o f 
apoptosis.
Nucleotide excision repa ir (NER) is  the p rim a ry  repa ir m echanism  
o f c isp la tin  DNA adducts. Damage is  detected in  NER pathw ays w ith  
XPC heterod im er and damaged DNA is unw ound  w ith  XPB and XPD 
enzymes. XPA and RPA associate and re c ru it excision enzymes XPF and 
XPG. RPA also re c ru its  PCNA, DNA polymerase and DNA ligase [45].
XPA and RPA, NER pro te ins, b in d  c isp la tin  adducts w ith  a h igher a ffin ity  
tha n  oxa lip la tin , a c isp la tin  derivative [8]. W ith  NER occu rring  more 
frequen tly  in  c isp la tin  treated cells, there cou ld  be a greater rate o f repa ir 
and su rv iva l in  c isp la tin  treated cells as com pared to R fl-P tC b  and DM - 
PtCb treated cells.
M ism atch  repa ir (MMR) and trans les ion  synthesis ce llu la r 
m ach inery are also activated by c isp la tin  adducts. M M R is a h ig h ly
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conserved re p a ir m echanism  th a t begins w ith  recogn ition  o f base pa ir 
m ism atches (by M utSa) o r inse rtion -de le tion  loops (by MutSP). Next 
hM LH 1 he te rod im er is recru ited , w h ich  in  tu rn  re c ru its  the  pro te ins 
responsible fo r s trand  d isc rim in a tio n  and DNA endonuclease activ ity , 
w h ich  have ye t to be determ ined in  hum ans. The m ism atched base is 
removed by exonuclease ac tiv ity , replaced and ligated [45]. hM utS a , a 
hum an  M M R pro te in , is  responsible fo r the  recogn ition  c isp la tin  adducts 
[42]. The M M R process is  th o u g h t to be ineffective a t repa ir in  c isp la tin  
treated cells, because any nucleotide can be placed opposite the lesion 
b u t the ad du c t w ill no t be removed. I f  NER pro te ins do no t b in d  w ith  
great a ff in ity  to  the larger R fl-P tC b  and D M -P tC b adducts, MMR 
pro te ins m ay b in d  pre fe ren tia lly  and engage in  a ‘fu tile  cycle ’ w ith o u t 
rem oving the  lesion. Th is un repa ired  damage cou ld  lead to an increase 
in  apoptosis signaling. Apoptosis m ay also occur due to low  fide lity  
trans les ion  synthesis past the larger R fl-P tC b  and D M -P tC b lesions. 
DNA polym erase q and (3 in se rt m ism atches opposite c isp la tin  adducts 
d u rin g  synthesis [8]. E rro r-p rone  synthesis m ay occur m ore frequen tly  
o r to a greater exten t in  R fl-P tC b  and D M -P tC b treated cells.
Some o f the  nonh istone chrom atin -associa ted p ro te in  fa m ily  (HMG 
protein) b in d  p la tin u m  adducts and prevent in te rac tions  w ith  repa ir 
p ro te ins [8]. The a b ility  o f these p ro te ins to d iscrim ina te  between 
c isp la tin , R fl-P tC b  and D M -P tC b adducts m ay exp la in  the  difference in  
tox ic ity .
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To e lucidate the action  o f these drugs and the po ten tia l the rapeu tic  
uses o f these d rugs fu r th e r stud ies shou ld  be carried out. To determ ine 
the  effect o f the flu o ro u s  4 ,4 ’- su b s titue n t, a su rv iva l assay shou ld  be 
done us in g  2 ,2 ’-b ip yrid in e -P tC b . A  4 ,4 ’-b u ty l-2 ,2 ’-b ip y rid in e -P tC b , the 
equ iva lent length  o f the  R fl-P tC b  w ith o u t fluo rine , shou ld  be synthesized 
and assayed fo r b io log ica l effects. Th is  m ay elucidate any effect the 
fluo rine  sub s titu e n ts  have on the cy to tox ic ity  o f the drug. D rug  de livery 
to  breast cancer cells can be im proved by covalently te the ring  these 
drugs to estrogen m olecules [46]. Th is  m ay increase efficacy o f the  drugs 
in  ER+ breast cancer cell lines.
The cu rre n t drugs, R fl-P tC b  and DM -PtCb, are ready fo r sm a ll 
an im a l studies. A n im a l s tud ies w ill be necessary to determ ine the side 
effects o f the drugs, the  c lin ica lly  effective dose and to determ ine i f  i t  is 
reasonable to look a t these d rugs as a lte rna tive  chem otherapies fo r 
c isp la tin  patients.
C e llu la r m echan ism s also need to be better understood fo r these 
dm gs and c isp la tin . A n in it ia l step is  to assess changes in  p ro te in  
expression. Th is can be done w ith  a DNA m icroarray before and a fte r 
trea tm ent. A m ic ro a rray  w ou ld  give an overview o f a ll p ro te ins expressed 
in  the cell and w ou ld  show differences, i f  any, between trea tm en t groups. 
I t  is possible th a t d iffe ren t re pa ir p ro te ins are being pre fe ren tia lly  
overexpressed in  cells treated w ith  the d iffe ren t drugs. Th is  m ay he lp 
determ ine w h ich  re pa ir pathw ays, w h ich  damage recogn ition  p ro te ins
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and w h ich  tra n sc rip tio n  factors are being used. To determ ine the 
efficacy o f trans les ion  synthesis o f these lesions a previous technique by 
Chaney can be used [8]. Chaney looked fo r a correct inse rtion  opposite 
p la tin u m  adducts, as com pared to  undam aged DNA us ing  two d iffe ren t 
DNA polymerases.
F ina lly , de te rm in ing  the loca tion  o f p la tin u m  adducts and types o f 
adducts  in  a cell shou ld  be carried  ou t. The exten t o f c isp la tin , R fl-P tC b  
and D M -P tC b b in d ing  to p ro te ins can be done by a p rec ip ita tion  o f 
p ro te ins from  cell lysate, and subsequent analys is fo r d rug  content. To 
com pare the  DNA adducts o f the  three com pounds. X -ray  crysta llography 
shou ld  be carried  o u t on 10 nucleotide leng ths o f dup lex DNA. The 
bending o f DNA by c isp la tin  is th o u g h t to  a lte r its  a ff in ity  fo r ce rta in  
damage recogn ition  prote ins. D e te rm in ing  the  exten t o f bending o f DNA 
when bound  to drugs m ay be v ita l to un de rs tan d ing  the m echanism s o f 
to x ic ity  and apoptosis.
4.3 S um m ary
Novel c isp la tin  derivatives were successfu lly  synthesized and 
assayed fo r b io logica l effects. The drugs were tested in  fou r breast 
cancer cell lines, DC4, DB46, M D A -M B -435 and M D A-M B-231. R f l-  
P tCb and D M -P tC b were found to  have low er ECso values than  c isp la tin . 
R fl-Re(CO )3 Cl and DM-Re(CO)3 Cl were found  to be ineffective a t ind u c in g  
cell death in  DC4 and DB46. In  m ost cases, R fl-P tC b  and D M -P tC b
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were fou nd  to induce  apoptosis and necrosis a t h ighe r rates than  
c isp la tin , accord ing to A nnexin  V  s ta in ing  and m icroscopy. F ina lly , 
accord ing to PI s ta in ing  and analysis w ith  flow  cy tom etiy , R fl-P tC b  and 
D M -P tC b in h ib it  the  cell cycle a t d iffe ren t phases th a n  c isp la tin . In  
conclusion , these da ta  suggest R fl-P tC b  and DM -P tC b are effective 
inducers o f cell death in  breast cancer cells, and w o rk  k in e tica lly  and 
m echan is tica lly  d iffe ren t th a n  c isp la tin .
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APPENDIX I 
NMR SPECTRA
75
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CD
■ D
OQ.
C
gQ.
■D
CD
C/)
C/)
8
(O '
3.
3 "
CD
CD■D
OQ.
C
a
o3
"O
o
CDQ.
■D
CD
C/)
C/)
r>. o  --H r*- m  c \j «H ( I If) fu in r*- <\i CO
in  If)  r*» < 
i^CSCSCDCDIDffir^
<1o\
L IA *AiVAW/rt'Mr
Current Data Parameters
NAME p ro to n l
EXPNO 3
PnOCND 2
F2 -  A c q u is it io n  Parameters
Date 500000
Time 1.3B
PULPROG zg
SOLVENT CDC13
AO 1.9640200 sec
FIORES 0.252015 Hz
DW 52.0 usee
RG 1024
NUCLEUS IH
HLl 0 dB
01 1.0000000 sec
PI 5 .0  usee
OE SB.5 usee
SFOl 400.1381000 MHz
SWH B064.52 Hz
TD 32000
NS 16
OS 0
FI -  Processing parameters
SI 163B4
HC2 OF
SF 400.1364726 MHz
HOW EM
SSB 0
LB 0.10 Hz
GB 0
%
ID NMH p lo t parameters 
CX 20.00 cm
F IP 9.259 ppm
F I 3705.00 Hz
F2P -0.301 ppm
F2 -120.33 Hz
'^PMCM 0.47800 ppm/cm
HZCM 191.2BB31 Hz/cm
X
3
X
o
X
!
f -
s
I
13C NMR of R fl Ligand in CDCI3
OT in oi oj
( O - O - O M S S Z X
u f n o c n o c o u o o j i n o f n m o o ' ^ ^ A  o * - » ^ o  to m o  fu V, o  • * 0 ) 0 ^ 0oicjoj(vitor«^o ocDOj-^ -^oo
N o n o i ^ r o  o  o  o i t n o n i^^  w m o  o  tom 10
O) ^  m o  (VI AI oj
* * a iu . r> .3C O o o
g  r<  o  g  ÜJ o
o  o> m to t:* t n o c n ( D t o ^ « ^ < D  L • fn • ^  • to O)
0 ) 0  ‘ O) • O  AJ 03^ O j A f f O t O I M V O I
cu to ro I ID • •
e  V» lo  I CD
9 Ï S 2 -----------------
ZÏOO —
I 01 a* o. >
A I m  —  3  o  <
i i .  o  I— O- tn  •
t D 3 ^ A i _ i « - » « - w 2 z o ( n ( n  
l O C Z O C O X a C L O t O C / l i — Z C 3
t89 22
019 22
(86 22
^96 82
2^9 62
60tr OE
(9^ 2E
Z^O EE
I^EEEE
029 EE
96( > E
96ZBE
6 8 2 '6 ^
0 6 t '8 9
(6 9 '9 Z
900 ZZ 
92E ZZ
OBJ-(21
0^9 E2Î
E28 E2Ï
Z6Z ^2(
^ 8 9 '9 2 :
968 921
2EE 82T
BZO TEI
862 9 9 ( -  
u idd
77
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CD
■ D
O
Q.
C
g
Q.
"D
CD
C/)
C/)
CD
8
3
3 "
CD
CD■D
O
Q.
C
aO3
"O
O
CD
Q.
■D
CD
C/)
C/)
1^ OJ OJ OJ cv
o
00
Current Data Parameters
NAME f l9
EXPNO 1
PROCNQ 1
F2 -  A c q u is it io n  Parameters
Date 500000
Time 19.43
PULPROG zg
SOLVENT CDC13
AQ 1 .OBI3640 sec
FIDRES 0.462388 Hz
DW 66.0 usée
RG 4096
NUCLEUS 19F
HLl 3 OB
FLl 60 PB
01 4.0000000 sec
PI 11.3 usée
DE 94.3 usée
SFOl 376.4790000 MHz
SWH 7575.76 HZ
TD 16384
NS 16
DS 0
FI -  Processing parameters
SI 8192
MC2 QF
SF 376.5043910 MHz
WDW no
SSB 0
LB 0.00 Hz
GB 0
ID NMR p l o t  parameters 
CX 20.00 cm
FIP -70.809 ppm
FI -25659.99 Hz
-71.708 ppm 
-26998.32 Hz 
:M 0.04493 ppm/cm
I 16.91659 Hz/cm
r .M
a
3'
oaoc3^
CD
■ D
O
Q.
C
8
Q.
■D
CD
C/)
C/)
8
ci'
3
3"
CD
CD■D
O
Q.
C
aO
3
■D
O
CD
Q.
■D
CD
C/)
C/)
O) m o  Vi r  V  o  in mr-. ^  m ru 1 g  2 S I I
m rû eu ai
L  L L
“ ® S „o i f nu 3 r * * . < i 3Œî f > j i o n j ( û r uoc n « mc D  r u o G O ^ v c D m r ^ r u t D ^ m ^ - o c o r -  l O O G O C D r ^ i D t D t n m ' T  TT r u o o o  oj»-LU iw  vy u j  ^  u /  LU 1-^o o o o o o o o o o o o o  O Current Date Parameters 
a j r u f u r u r ü n j f û p j r u r u a j a l n j a j o j o j o d d  dhJAME proton2
...........................   ' ' 3
1
L W U J
I
F2 -  Acquis
Date
Time
PULPROG
SOLVENT
AQ
FIDRES
DW
RG
NUCLEUS
HLl
01
PI
DE
SFOl
SWH
TD
NS
OS
i t i o n  Parameters 
710303 
1.12 
29 
CDD 13 
2.9153721 sec 
0.171447 Hz 
89.0 usée 
2048 
IH
0 dS
1.0000000 sec 
5.0 usée 
127.1 usée 
400.1382000 MHz 
5617.98 Hz 
32758 
258 
0
FI -  Processing parameters
16384
OF
400.1364715 MHz
o'
WDW no
SSB 0
LB 0.00 Hz
GB 0
10 NMR p lo t parameters
rCX 20.00 cm
FIP 10.423 ppm
FI 4170.52 HZ
F2P -0.478 ppm
F2 -191.18 Hz
PPMCM 0.54503 ppm/cm
HZCM 218.08479 Hz/cm
X
3
§
%
i
s
(D
In>
CD
■ D
O
Q.
C
8
Q.
"O
CD
C/)
C/)
CD
8
3.
3"
CD
CD■D
O
Q.
C
aO
3
■D
O
CD
Q.
■D
CD
C/)
C/)
m ^ ^ * - ' ^ o o o o o
00O
ppm 1 5 0 1 4 0 120 100 8 0
C urre n t Data Parameters
NAME carbons
EXPNO 3
PROCNO
Ç
1
|^F2 -  A cqu is i t io n  Parameters
S  Date 970407
J Time 
/  PULPROG 
SOLVENT
21.44
zgdc
CDC13
AQ 1.2615080 sec
FIDRES 0.396332 HZ
DW 22.0 usee
RG 2048
NUCLEUS 13C
DU 0.0300000 sec
S2 22 dB
HLl 15 dB
D1 5.0000000 sec
PI 8 .3 usee
DE 31.4 usee
SFOl 100.6272860 MHz
SWH 22727.27 HZ
TD 57344
NS 2096
DS 0
F I -  P rocessing  parameters 
SI 131072
MC2 QF
SF 100.6142130 MHz
WDW EM
SSB 0
4 .00 Hz
0 NMfi p lo t  parameters
t x 20.00 cm
f l P 171.931 ppm
FI 17298.68 Hz
F2P 19.827 ppm
F2 1994.89 HZ
PPMCM 7.60518 ppm/cm
HZCM 755.18945 Hz/cm
w
O
%1—a
i
5'
a.
Rft
o5
f t
NMR of Rfl-PtCla in de-acetone
I m  ot <n o
£?■
X 3  - a T 3 < n 3 3 Z X
^ o m i L O O O o r ^ o t o i o r u c  in >0)0) to o  • 'O t j i tn mm m w *1 o  »-• in o  « tn
romoo o  ps o  m m
to to M
j i
. o  (O œ CO • Lj Ü. u. tA. u. Q. :
P90QZ-
ZGogg-
t^ 0S2-
ZH
81
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
iR  NMR of DM-PtCb in d-DMSO
;WOOS'2- 
99n s ' 2-
OEETZ E-
92zrs
ZSW6E 8 -
EESO'I
8 9 Z 0 'l
0000'I
ie jf ia ;u T
82
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CD
■ D
O
Q.
C
g
Q.
■D
CD
C/)
C/)
8
ci'
n  ^  iD CD o  m2 S R Si Pi z §
3.
3"
CD
CD■D
O
Q.
C
aO
3
■D
O
CD
Q.
■D
CD
C/)
C/)
00Co
ppm 1 40 1 20 100 8 0
-n-p-r
40 20
Current Data Parameters
NAME carbons
EXPNO 3
PROCNO 2
F2 -  A c q u is it io n  Parameters
Date 970416
Time 15.33
PULPROG zgdc
SOLVENT CDC13
AQ 1.4418120 sec
FIDRES 0.346791 HZ
DW 22.0 usée
RG 2048
NUCLEUS 13C
DU 0.0300000 sec
S2 22 dB
HLl 15 dB
01 2.0000000 sec
PI 8 .3  usée
OE 31.4 usée
SFOl 100.6240000 MHz
SWH 22727.27 HZ
TD 65535
NS 6000
DS 0
F I -  Processing parameters
SI 131072
MC2 QF
SF 100.6144185 MHZ
WDW EM
SS8 0
LB 4.00 HZ
GB 0
18 NMR p lo t  parameters 
CX 20.00 cm
FlP 153.336 ppm
1 16433.96 HZ
2P -5 .226 ppm
V2 -525.84 HZ
PPMCM 8.42811 ppm/cm
HZCM 847.98987 HZ/cm
W
O
%
o
D
œ
O
iH  NMR of Rfl-Re(CO)3Cl in CDCI3
s s § s
o  o  o  (O  I ' 00 U- CO 0 0 0 0
Zt 981-
z6 zei-
^ i sI 0) m Q_ >
c\j I0  ^ o  I Li_ o h- CL cn ■ O Q . a c n c n i — Z C 3  u . • o ul a  to CD 00I z  m 3E tn _i Cl
(5 *9 2 (------^ 1  ^ E / * / 2l£'Hl------Æ — - 699*^2E6 20Ï —
Z9QI- 
90 89- 
AB9S-  
59
9 E Ï 8 5  
66 0(9  
21*209 
22-EE9 
92 2^9 
t l £ 9 9  
EE ■ 1^ 99 
E 9 l £ ^ I - \ ^  
2 ^ ' 2 E ^ ( - ^  
19'9Ï9I~^ ^^  
trr8ï9ï—^7
0 C 2 6 Z t - ^  
EZ*(^6ZÎ-V 
Z 9V 6^(-
LZL'LZ
(99*92
9/2*92
9/9  (9
11
9 2 / ^ 2
9 (0*^2
WE'WEEE-
ZH
84
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CD
■ D
O
Q.
C
g
Q.
■D
CD
(/)
C/)
8
CD
3.
3"
CD
CD■D
O
Q.
C
aO
3
■D
O
CD
Q.
■D
CD
C/)
C/)
00
en
O) CT en lo CTl (\J V  
m ° ® m  r »  iD  r s  ®  ooCM ^  r u  r nCM m  CM en ®
œ  f>- ID  CM 
CM CM CM CM
en en  CM CM CM 
m  en en  r o  en CM
ppm
C urrent Data Parameters
NAME carbons
EXPNO 3
PROCNO 1
F2 -  A c q u is it io n  Parameters
Date 710402
Time 0.04
PULPROG zgdc
SOLVENT CDC13
AQ 1.26158B0 sec
FIDRES 0.396332 Hz
DW 22.0 usee
RG 2048
NUCLEUS 13C
DU 0.0300000 SBC
S2 22 dB
HLl 15 dB
D1 5.0000000 sec
PI 8 .3 usee
DE 31.4 usee
SFOl 100.6240000 MHz
SWH 22727.27 Hz
TO 57344
NS 10000
DS 0
F I -  P rocessing  param eters
SI 131072
MC2 OF
SF 100.6138727 MHz
WDW EM
SSB 0
LB 2.00
0
Hz
10 NMR p lo t param eters
CX
rFlP
20.00
213.598
cm
ppm
FI 21490.93 Hz
F2P -12.288 ppm
F2 -1236.34 HZ
PPMCM 11.29430 ppm/cm
HZCM 1136.35365 Hz/cm
co
0
s
s,
%
1oo
'cô^o
3"
o
D
O
oT
19F NMR of Rfl-Re(CO)3 Cl in CDCI3
m g
o > (* )0 ' > - * o r v j L i . o o o o r * > ’ 0 ( Oco r uo  
tnNr-icDtn ' O) too « o c* m m • o w ^ t n o  - m
o «-• o (*) in
o r*. fo to
o  ru oï en ^o  -V ro in o I s '
.00 o o  o  o o  V# V r-L I
in o 01 '9  co (M I
ai o -ru * I
*A cu o ^ « o Is T s T s .
ü_a*-c^to<ü.occzxi 's i s
86
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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C om parison o f Cell Lines Using S tuden t’s T Test and Tukey Test 
L S M e a n s  D i f f e r e n c e s  S t u d e n t ' s  t
Alpha=
0.050 t=
Mean[i]-Meant|] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif
DB46 DC4 MDAMB
231
MDAMB
435
D B46 0 3.94C-6 -3.6e-5 -5.3e-5
0 0.00003 0.00002 0.00003
0 -4.9e-5 -8.7e-5 -0.0001
0 0.00006 0.00001 2.72e-6
DC4 -3.9e-6 0 -4e-5 -5.7e-5
0.00003 0 0.00003 0.00003
-5.7e-5 0 -9.3e-5 -0.0001
0.00005 0 0.00001 7.26C-7
MDA MB 2 3 1 0.00004 0.00004 0 -1.7e-5
0.00002 0.00003 0 0.00003
-1.4C-5 -1.3e-5 0 -7.3e-5
0.00009 0.00009 0 0.00004
MDA MB 4 3 5 0.00005 0.00006 0.00002 0
0.00003 0.00003 0.00003 0
-2.7e-6 -7.3e-7 -3.9e-5 0
0.00011 0.00011 0.00007 0
Level
MDA MB 435 
MDAMB 231 
DB46 
DC4
A
A
A
A
Least Sq Mean 
0.00006029 
0.00004356 
0.00000717 
0.00000323
Levels not connected by same letter are significantly different
L S M e a n s  D i f f e r e n c e s  T u k e y  H S D
Alpha=
0.050 Q=
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif
DB46 DC4 MDA MB 
231
MDAMB
435
DB46 0 3.94C-6 -3.6e-5 -5.3e-5
0 0.00003 0.00002 0.00003
0 -6.7e-5 -0.0001 -0.0001
0 0.00008 0.00003 0.00002
DC4 -3.9e-6 0 -4e-5 -5.7e-5
0.00003 0 0.00003 0.00003
-7.5e-5 0 -0.0001 -0.0001
0.00007 0 0.00003 0.00002
MDAMB 2 3 1 0.00004 0.00004 0 -1.7e-5
0.00002 0.00003 0 0.00003
-3.2e-5 -3.1e-5 0 -9.2e-5
0.0001 0.00011 0 0.00006
MDA MB 4 3 5 0.00005 0.00006 0.00002 0
0.00003 0.00003 0.00003 0
-2.2e-5 -2.1C-5 -5.8e-5 0
0.00013 0.00013 0.00009 0
Level Least Sq Mean
MDA MB 435 A 0.00006029
MDA MB 231 A 0.00004356
DB46 A 0.00000717
DC4 A 0.00000323
Levels not connected by same letter are significantly different
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Comparison of Drugs Using Student’s T Test and Tukey Test
L east Squares M eans Table
Level Least Sq Mean Std Error Mean
Cisplatin 0.00007878 0.00001732 0.000074
DM-Pt 0.00000376 0.00001604 0.000004
Rfl-Pt 0.00000316 0.00001447 0.000003
L S M e a n s  D i f f e r e n c e s  S t u d e n t ' s  t  
Alpha=
0.050 t=
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif
Cisplatin DM-Pt Rfl-Pt
C isplatin 0 0.00008 0.00008
0 0.00002 0.00002
0 0.00003 0.00003
0 0.00012 0.00012
DM-Pt -7.5e-5 0 5.97e-7
0.00002 0 0.00002
-0.0001 0 -4.5e-5
-2.6e-5 0 0.00005
R fl-P t -7.6e-5 -6e-7 0
0.00002 0.00002 0
-0.0001 -4.6e-5 0
-2.9e-5 0.00004 0
Level Least Sq Mean
Cisplatin A 0.00007878
DM-Pt B 0.00000376
Rfl-Pt B 0.00000316
Levels not connected by same letter are significantly different
L S M e a n s  D i f f e r e n c e s  T u k e y  H S D
Alpha=
0.050 Q=
Mean[i]-Meantj] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif
Cisplatin DM-Pt Rfl-Pt
C isplatin 0 0.00008 0.00008
0 0.00002 0.00002
0 0.00002 0.00002
0 0.00014 0.00013
DM-Pt -7.5e-5 0 5.97e-7
0.00002 0 0.00002
-0.0001 0 -5.4e-5
-1.5e-5 0 0.00006
R fl-P t -7.6e-5 -6e-7 0
0.00002 0.00002 0
-0.0001 -5.5e-5 0
-1.9e-5 0.00005 0
Level
Cisplatin A 
DM-Pt B
Rfl-Pt B
Levels not connected
Least Sq Mean 
0.00007878 
0.00000376 
0.00000316 
by same letter are significantly different
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Comparison of Cell Lines Treated with Cisplatin Using Student’s T Test
and Tukey Test
L S M e a n s  D i f f e r e n c e s  S t u d e n t ' s  t
Alpha=
0.050 t=
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif
DB46 DC4 MDAMB
231
MDA MB
435
D B46 0 -7.3e-7 -0.0001 -0.0002
0 1.58e-6 1.58e-6 1.93e-6
0 -5.7e-6 -0.0001 -0.0002
0 4.29e-6 -0.0001 -0.0002
DC4 7.3e-7 0 -0.0001 -0.0002
1.58e-6 0 1.58e-6 1.93e-6
-4.3e-6 0 -0.0001 -0.0002
5.75e-6 0 -0.0001 -0.0002
MDA MB 2 3 1 0.00013 0.00013 0 -0.0001
1.58e-6 1.58e-6 0 1.93e-6
0.00012 0.00012 0 -0.0001
0.00013 0.00013 0 -9.9e-5
MDAMB 4 3 5 0.00023 0.00023 0.00011 0
1.93e-6 1.93e-6 1.93e-6 0
0.00023 0.00023 0.0001 0
0.00024 0.00024 0.00011 0
Level
MDA MB 435 A 
MDA MB 231 B
DC4 C
DB46 C
Levels not connected by same letter
Least Sq Mean 
0.00023714 
0.00013199 
0.00000502 
0.00000429 
are significantly different
L S M e a n s  D i f f e r e n c e s  T u k e y  H S D
Alpha=
0.050 Q -
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif
DB46 DC4 MDA MB
231
MDA MB 
435
DB46 0 -7.3e-7 -0.0001 -0.0002
0 1.58e-6 1.58e-6 1.93e-6
0 -8.3e-6 -0.0001 -0.0002
0 6.87e-6 -0.0001 -0.0002
DC4 7.3e-7 0 -0.0001 -0.0002
1.58e-6 0 1.58e-6 1.93e-6
-6.9e-6 0 -0.0001 -0.0002
8.34e-6 0 -0.0001 -0.0002
MDA MB 2 3 1 0.00013 0.00013 0 -0.0001
1.58e-6 1.58e-6 0 1.93e-6
0.00012 0.00012 0 -0.0001
0.00014 0.00013 0 -9.6e-5
MDA MB 4 3 5 0.00023 0.00023 0.00011 0
1.93e-6 1.93e-6 1.93e-6 0
0.00022 0.00022 0.0001 0
0.00024 0.00024 0.00011 0
Level
MDA MB 435 A 
MDAMB 231 B
DC4 C
DB46 C
Levels not connected by same letter
Least Sq Mean 
0.00023714 
0.00013199 
0.00000502 
0.00000429 
are significantly different
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Comparison of Cell Lines Treated with R fl-P tC b Using Student’s T Test
and Tukey Test
L S M e a n s  D i f f e r e n c e s  S t u d e n t ' s  t
Alpha= 
0.050 t=
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif
DB46 DC4 MDAMB
231
MDA MB 
435
DB46 0 3.3e-6 2.72e-6 2.96e-6
0 1.65e-6 1.5e-6 1.65e-6
0 -9.4e-7 - l. le -6 -1.3e-6
0 7.53e-6 6.58e-6 7.19e-6
DC4 -3.3e-6 0 -5.8e-7 -3.4e-7
1.65e-6 0 1.5e-6 1.65e-6
-7.5e-6 0 -4.4e-6 -4.6e-6
9.36e-7 0 3.28e-6 3.9e-6
MDA MB 2 3 1 -2.7e-6 5.82e-7 0 2.46e-7
1.5e-6 1.5e-6 0 1.5e-6
-6.6e-6 -3.3e-6 0 -3.6e-6
1.15e 6 4.45e-6 0 4.11e-6
MDAMB 4 3 5 -3e-6 3.36e-7 -2.5e-7 0
1.65e-6 1.65e-6 1.5e-6 0
-7.2e-6 -3.9e-6 -4.1e-6 0
1.27e-6 4.57e-6 3.62e-6 0
Level
DB46
MDA MB 231 
MDA MB 435 
DC4
A
A
A
A
Least Sq Mean 
0.00000488 
0.00000216 
0.00000192 
0.00000158
Levels not connected by same letter are significantly different
L S M e a n s  D i f f e r e n c e s  T u k e y  H S D
Alpha=
0.050 Q -
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif
DB46 DC4 MDAMB
231
MDAMB
435
DB46 0 3.3e-6 2.72e-6 2.96e-6
0 1.65e-6 1.5e-6 1.65e-6
0 -2.8e-6 -2.8e-6 -3.1e-6
0 9.37e-6 8.26e-6 9.04e-6
DC4 “3.3e-6 0 -5.8e-7 -3.4e-7
1.65e-6 0 1.5e-6 1.65e-6
-9.4e-6 0 -6.1e-6 -6.4e-6
2.78e-6 0 4.97e-6 5.74e-6
MDA MB 23 1 -2.7e-6 5.82e-7 0 2.46e-7
1.5e-6 1.5e-6 0 1.5e-6
-8.3e-6 -5e-6 0 -5.3e-6
2.83e-6 6.13e-6 0 5.79e-6
MDA MB 4 3 5 -3e-6 3.36e-7 -2.5e-7 0
1.65e-6 1.65e-6 1.5e-6 0
-9e-6 -5.7e-6 -5.8e-6 0
3.12e-6 6.41e-6 5.3e-6 0
Level Least Sq Mean
DB46 A 0.00000488
MDA MB 231 A 0.00000216
MDA MB 435 A 0.00000192
DC4 A 0.00000158
Levels not connected by same letter are significantly different
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Comparison of Cell Lines Treated with DM-PtCb Using Student’s T Test
and Tukey Test
L S M e a n s  D i f f e r e n c e s  S t u d e n t ' s  t
Alpha=
0.050 t=
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif
DB46 DC4 MDAMB
231
MDAMB
435
DB46 0 -8.4e-7 -2.3e-6 -2.9e-6
0 1.67e-6 1.67e-6 1.67e-6
0 -5.5e-6 -6.9e-6 -7.5e-6
0 3.8e-6 2.38e-6 1.76e-6
DC4 8.37e-7 0 -1.4e-6 -2e-6
1.67e-6 0 1.67e-6 1.67e-6
-3.8e-6 0 -6.1e-6 -6.7e-6
5.48e-6 0 3.22e-6 2.59e-6
MDA MB 2 3 1 2.26e-6 1.42e-6 0 -6.3e-7
1.67e-6 1.67e-6 0 1.67e-6
-2.4e-6 -3.2e-6 0 -5.3e-6
6.9e-6 6.06e-6 0 4.01e-6
MDA MB 4 3 5 2.88e-6 2.05e-6 6.27e-7 0
1.67e-6 1.67e-6 1.67e-6 0
-1.8e-6 -2.6e-6 -4e-6 0
7.52e-6 6.68e-6 5.27e-6 0
Level Least Sq Mean
MDA MB 435 A 0.00000514
MDAMB 231 A 0.00000452
DC4 A 0.0000031
DB46 A 0.00000226
Levels not connected by same letter are significantly different
L S M e a n s  D i f f e r e n c e s  T u k e y  H S D
Alpha=
0.050 Q=
Mean[i]-Meantj] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif
DB46 DC4 MDAMB
231
MDAMB
435
DB46 0 -8.4e-7 -2.3e-6 -2.9e-6
0 1.67e-6 1.67e-6 1.67e-6
0 -7.6e-6 -9.1e-6 -9.7e-6
0 5.97e-6 4.55e-6 3.92e-6
DC4 8.37e 7 0 -1.4e-6 -2e-6
1.67e-6 0 1.67e-6 1.67e-6
-6e-6 0 -8.2e-6 -8.8e-6
7.64e-6 0 5.38e-6 4.76e-6
MDAMB 2 3 1 2.26e-6 1.42e-6 0 -6.3e-7
1.67e-6 1.67e-6 0 1.67e-6
-4.5e-6 -5.4e-6 0 -7.4e-6
9.06e 6 8.22e-6 0 6.18e-6
MDA MB 4 3 5 2.88e-6 2.05e-6 6.27e-7 0
1.67e-6 1.67e-6 1.67e-6 0
-3.9e-6 -4.8e-6 -6.2e-6 0
9.69e-6 8.85e-6 7.43e-6 0
Level Least Sq Mean
MDA MB 435 A 0.00000514
MDA MB 231 A 0.00000452
DC4 A 0.0000031
DB46 A 0.00000226
Levels not connected by same letter are significantly different
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Com parison o f D rugs on DC4 Cell Line U sing S tuden t’s T Test
L S M e a n s  D i f f e r e n c e s  S t u d e n t ' s  t
Alpha=
0.050 t=
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif
Cisplatin DM-Pt Rfl-Pt
C isplatin 0 1.92e-6 3.44e-6
0 9.02e-7 9.02e-7
0 -9.5e-7 5.68e-7
0 4.79e-6 6.31e-6
DM-Pt -1.9e-6 0 1.52e-6
9.02e-7 0 9.02e-7
-4.8e-6 0 -1.4e-6
9.51e-7 0 4.39e-6
R fl-P t -3.4e-6 -1.5e-6 0
9.02e-7 9.02e-7 0
-6.3e-6 -4.4e-6 0
-5.7e-7 1.35e-6 0
Level
Cisplatin A 
DM-Pt A B 
Rfl-Pt B
Levels not connected by
Least Sq Mean 
0.00000502 
0.0000031 
0.00000158 
same letter are significantly different
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Comparison of Drugs on DB46 Cell Line Using Student’s T Test and
Tukey Test
L S M e a n s  D i f f e r e n c e s  S t u d e n t ' s  t
Alpha=
0.050 t=
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif
Cisplatin DM-Pt Rfl-Pt
C isp latin 0 2.03e-6 3.83e-7
0 1.98e-6 1.81e-6
0 -3.5e-6 -4.6e 6
0 7.52e-6 5.4e-6
DM-Pt -2e-6 0 -1.6e-6
1.98e-6 0 1.81e-6
-7.5e-6 0 -6.7e-6
3.47e-6 0 3.37e-6
R fl-P t -3.8e-7 1.64e-6 0
1.81e-6 1.81e-6 0
-5.4e-6 -3.4e-6 0
4.63e-6 6.66e-6 0
Level
Cisplatin A 
Rfl-Pt A
DM-Pt A
Levels not connected
Least Sq Mean 
0.00000429 
0.0000039 
0.00000226 
by same letter are significantly different
L S M e a n s  D i f f e r e n c e s  T u k e y  H S D
Alpha=
0.050 Q=
Mean[i]-Meantj] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif
Cisplatin DM-Pt Rfl-Pt
C isp latin 0 2.03e-6 3.83e-7
0 1.98e-6 1.81e-6
0 -5e-6 -6.1e-6
0 9.08e-6 6.82e-6
DM-Pt -2e-6 0 -1.6e-6
1.98e-6 0 1.81e-6
-9.1e-6 0 -8.1e-6
5.03e-6 0 4.8e-6
R fl-P t -3.8e-7 1.64e-6 0
1.81e-6 1.81e-6 0
-6.8e-6 -4.8e-6 0
6.06e-6 8.08e 6 0
Level
Cisplatin A 
Rfl-Pt A
DM-Pt A
Levels not connected
Least Sq Mean 
0.00000429 
0.0000039 
0.00000226 
by same letter are significantly different
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Comparison of Drugs on MDA-MB-435 Cell Line Using Student’s T Test
and Tukey Test
L S M e a n s  D i f f e r e n c e s  S t u d e n t ' s  t
Alpha=
0.050 t=
Mean[i]-Mean[j] 
std Err Dif 
Lower CL Dif 
Upper CL Dif
Cisplatin DM-Pt Rfl-Pt
C isplatin 0 0.00023 0.00024
0 2.39e-6 2.39e-6
0 0.00022 0.00022
0 0.00024 0.00025
DM-Pt -0.0002 0 3.23e-6
2.39e-6 0 1.95e-6
-0.0002 0 -5.2e-6
-0.0002 0 0.00001
R fl-P t -0.0002 -3.2e-6 0
2.39e-6 1.95e-6 0
-0.0002 -1.2e-5 0
-0.0002 5.17e-6 0
Level
Cisplatin A 
DM-Pt B
Rfl-Pt B
Levels not connected
Least Sq Mean 
0.00023714 
0.00000514 
0.00000192 
by same letter are significantly different
L S M e a n s  D i f f e r e n c e s  T u k e y  H S D
Alpha=
0.050 Q=
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif
Cisplatin DM-Pt Rfl-Pt
C isplatin 0 0.00023 0.00024
0 2.39e-6 2.39e-6
0 0.00022 0.00022
0 0.00025 0.00025
DM-Pt -0.0002 0 3.23e-6
2.39e-6 0 1.95e-6
-0.0002 0 -8.3e-6
-0.0002 0 0.00001
R fl-P t -0.0002 -3.2e-6 0
2.39e-6 1.95e-6 0
-0.0002 -1.5e-5 0
-0.0002 8.28e-6 0
Level
Cisplatin A 
DM-Pt B
Rfl-Pt B
Levels n o t connected
Least Sq Mean 
0.00023714 
0.00000514 
0.00000192 
by same letter are significantly different
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Comparison of Drugs on MDA-MB-231 Cell Line Using Student’s T Test
and Tukey Test
L S M e a n s  D i f f e r e n c e s  S t u d e n t ' s  t
Alpha=
0.050 t=
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL D if 
Upper CL Dif
Cisplatin DM-Pt Rfl-Pt
C isplatin 0 0.00013 0.00013
0 1.74e-6 1.59e-6
0 0.00012 0.00013
0 0.00013 0.00013
DM-Pt -0.0001 0 2.36e-6
1.74e-6 0 1.59e-6
-0.0001 0 -2.1e-6
-0.0001 0 6.77e-6
R fl-P t -0.0001 -2.4e-6 0
1.59e-6 1.59e-6 0
-0.0001 -6.8e-6 0
-0.0001 2.05e-6 0
Level
Cisplatin A 
DM-Pt B
Rfl-Pt B
Levels not connected by
Least Sq Mean 
0.00013199 
0.00000452 
0.00000216 
same letter are significantly different
L S M e a n s  D i f f e r e n c e s  T u k e y  H S D
Alpha=
0.050 Q=
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL D if
Cisplatin DM-Pt Rfl-Pt
C isplatin 0 0.00013 0.00013
0 1.74e-6 1.59e-6
0 0.00012 0.00012
0 0.00013 0.00014
DM-Pt -0.0001 0 2.36e-6
1.74e-6 0 1.59e-6
-0.0001 0 -3.3e-6
-0.0001 0 8.02e-6
R fl-P t -0.0001 -2.4e-6 0
1.59e-6 1.59e-6 0
-0.0001 -8e-6 0
-0.0001 3.31e-6 0
Level
Cisplatin A 
DM-Pt B
Rfl-Pt B
Levels not connected by
Least Sq Mean 
0.00013199 
0.00000452 
0.00000216 
same letter are significantly different
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